CN112851667A - 含氮并杂环类化合物及其药用组合物和应用 - Google Patents
含氮并杂环类化合物及其药用组合物和应用 Download PDFInfo
- Publication number
- CN112851667A CN112851667A CN202011294834.XA CN202011294834A CN112851667A CN 112851667 A CN112851667 A CN 112851667A CN 202011294834 A CN202011294834 A CN 202011294834A CN 112851667 A CN112851667 A CN 112851667A
- Authority
- CN
- China
- Prior art keywords
- radical
- alkyl
- aryl
- substituted
- nitrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 Nitrogen-containing heterocyclic ring compound Chemical class 0.000 title claims abstract description 114
- 239000000203 mixture Substances 0.000 title claims description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 61
- 229940002612 prodrug Drugs 0.000 claims abstract description 32
- 239000000651 prodrug Substances 0.000 claims abstract description 32
- 101000754913 Homo sapiens Serine/threonine-protein kinase RIO2 Proteins 0.000 claims abstract description 20
- 102100022090 Serine/threonine-protein kinase RIO2 Human genes 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- 150000003254 radicals Chemical class 0.000 claims description 169
- 238000006243 chemical reaction Methods 0.000 claims description 94
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 47
- 125000001072 heteroaryl group Chemical group 0.000 claims description 38
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 229910052736 halogen Inorganic materials 0.000 claims description 25
- 150000002367 halogens Chemical class 0.000 claims description 25
- 238000006467 substitution reaction Methods 0.000 claims description 25
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 24
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 24
- 150000002148 esters Chemical class 0.000 claims description 21
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 20
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 19
- 239000003112 inhibitor Substances 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 15
- 150000001408 amides Chemical class 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 8
- 125000003368 amide group Chemical group 0.000 claims description 8
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 3
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 3
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 3
- 201000006845 reticulosarcoma Diseases 0.000 claims description 3
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- OMBRFUXPXNIUCZ-UHFFFAOYSA-N dioxidonitrogen(1+) Chemical compound O=[N+]=O OMBRFUXPXNIUCZ-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229950008352 promoxolane Drugs 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 121
- 210000004881 tumor cell Anatomy 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 3
- 230000012010 growth Effects 0.000 abstract description 2
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 84
- 230000015572 biosynthetic process Effects 0.000 description 56
- 238000003786 synthesis reaction Methods 0.000 description 56
- 239000007787 solid Substances 0.000 description 49
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 48
- 238000005160 1H NMR spectroscopy Methods 0.000 description 45
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000012043 crude product Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 238000000967 suction filtration Methods 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 239000012065 filter cake Substances 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 10
- 238000010791 quenching Methods 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 150000003384 small molecules Chemical class 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 108091000080 Phosphotransferase Proteins 0.000 description 7
- 102000001253 Protein Kinase Human genes 0.000 description 7
- 238000009739 binding Methods 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 102000020233 phosphotransferase Human genes 0.000 description 7
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 7
- 108060006633 protein kinase Proteins 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 229940121649 protein inhibitor Drugs 0.000 description 6
- 239000012268 protein inhibitor Substances 0.000 description 6
- 230000000171 quenching effect Effects 0.000 description 6
- 238000002390 rotary evaporation Methods 0.000 description 6
- 239000011324 bead Substances 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000001308 synthesis method Methods 0.000 description 5
- 238000002626 targeted therapy Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- RSCTXUZWVYMQTL-UHFFFAOYSA-N COC(N=C1)=CC=C1C(C=C1)=CC(C2=C3C=NN2C(C=C2)=CC(C(F)(F)F)=C2N2CCNCC2)=C1NC3=O Chemical compound COC(N=C1)=CC=C1C(C=C1)=CC(C2=C3C=NN2C(C=C2)=CC(C(F)(F)F)=C2N2CCNCC2)=C1NC3=O RSCTXUZWVYMQTL-UHFFFAOYSA-N 0.000 description 4
- FAXQWGUHCYAKEC-UHFFFAOYSA-N COC(N=C1)=CC=C1C(C=C1)=CC(C2=C3N=CN2C(C=C2)=CC(C(F)(F)F)=C2N2CCNCC2)=C1NC3=O Chemical compound COC(N=C1)=CC=C1C(C=C1)=CC(C2=C3N=CN2C(C=C2)=CC(C(F)(F)F)=C2N2CCNCC2)=C1NC3=O FAXQWGUHCYAKEC-UHFFFAOYSA-N 0.000 description 4
- CPSDPBKUQGWAFX-UHFFFAOYSA-N COC(N=C1)=CC=C1C(C=C1)=CC(C2=C3N=NN2C(C=C2)=CC(C(F)(F)F)=C2N2CCN(CCN4CCOCC4)CC2)=C1NC3=O Chemical compound COC(N=C1)=CC=C1C(C=C1)=CC(C2=C3N=NN2C(C=C2)=CC(C(F)(F)F)=C2N2CCN(CCN4CCOCC4)CC2)=C1NC3=O CPSDPBKUQGWAFX-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 101000756066 Homo sapiens Serine/threonine-protein kinase RIO1 Proteins 0.000 description 4
- 108010047761 Interferon-alpha Proteins 0.000 description 4
- 102000006992 Interferon-alpha Human genes 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 102100022261 Serine/threonine-protein kinase RIO1 Human genes 0.000 description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 4
- DHADXDMPEUWEAS-UHFFFAOYSA-N (6-methoxypyridin-3-yl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=N1 DHADXDMPEUWEAS-UHFFFAOYSA-N 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 3
- RGHLRMNPUGUZEY-UHFFFAOYSA-N COC(N=C1)=CC=C1C(C=C1)=CC(C2=C3N=NN2C(C=C2)=CC(C(F)(F)F)=C2N2CCNCC2)=C1NC3=O Chemical compound COC(N=C1)=CC=C1C(C=C1)=CC(C2=C3N=NN2C(C=C2)=CC(C(F)(F)F)=C2N2CCNCC2)=C1NC3=O RGHLRMNPUGUZEY-UHFFFAOYSA-N 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 108010029961 Filgrastim Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 3
- 229960004338 leuprorelin Drugs 0.000 description 3
- 229960001614 levamisole Drugs 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 229960003787 sorafenib Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 2
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-CFWMRBGOSA-N 5j49q6b70f Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 OGWKCGZFUXNPDA-CFWMRBGOSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- QZZFKYXLPGVKRB-UHFFFAOYSA-N CC(C=C(C=C1)N2N=NC3=C2C(C=CC=C2)=C2NC3=O)=C1N1CCNCC1 Chemical compound CC(C=C(C=C1)N2N=NC3=C2C(C=CC=C2)=C2NC3=O)=C1N1CCNCC1 QZZFKYXLPGVKRB-UHFFFAOYSA-N 0.000 description 2
- OBQHNCNPCUJFAF-UHFFFAOYSA-N CC(N(CC1)CCN1C(C=C1)=C(C(F)(F)F)C=C1N1N=NC2=C1C(C=C(C=C1)C(C=N3)=CC=C3OC)=C1NC2=O)=O Chemical compound CC(N(CC1)CCN1C(C=C1)=C(C(F)(F)F)C=C1N1N=NC2=C1C(C=C(C=C1)C(C=N3)=CC=C3OC)=C1NC2=O)=O OBQHNCNPCUJFAF-UHFFFAOYSA-N 0.000 description 2
- XMIPOUJYIWEONJ-UHFFFAOYSA-N CC(N(CC1)CCN1C(C=C1)=C(C)C=C1N1N=NC2=C1C(C=C(C=C1)C(C=N3)=CC=C3OC)=C1N(CC(C=C1)=CC=C1OC)C2=O)=O Chemical compound CC(N(CC1)CCN1C(C=C1)=C(C)C=C1N1N=NC2=C1C(C=C(C=C1)C(C=N3)=CC=C3OC)=C1N(CC(C=C1)=CC=C1OC)C2=O)=O XMIPOUJYIWEONJ-UHFFFAOYSA-N 0.000 description 2
- IZQYQKXSCNXSMK-UHFFFAOYSA-N CC(N(CC1)CCN1C(C=CC(N1N=NC2=C1C(C=C(C=C1)C(C=N3)=CC=C3OC)=C1N(CC(C=C1)=CC=C1OC)C2=O)=C1)=C1OC)=O Chemical compound CC(N(CC1)CCN1C(C=CC(N1N=NC2=C1C(C=C(C=C1)C(C=N3)=CC=C3OC)=C1N(CC(C=C1)=CC=C1OC)C2=O)=C1)=C1OC)=O IZQYQKXSCNXSMK-UHFFFAOYSA-N 0.000 description 2
- SLALSOADYNPPOD-UHFFFAOYSA-N CN(C)CCN(CC1)CCN1C(C=C1)=C(C(F)(F)F)C=C1N1N=NC2=C1C(C=C(C=C1)C(C=N3)=CC=C3OC)=C1NC2=O Chemical compound CN(C)CCN(CC1)CCN1C(C=C1)=C(C(F)(F)F)C=C1N1N=NC2=C1C(C=C(C=C1)C(C=N3)=CC=C3OC)=C1NC2=O SLALSOADYNPPOD-UHFFFAOYSA-N 0.000 description 2
- KYKNTEXSDOHADZ-UHFFFAOYSA-N CN(CC1)CCN1C(C=C1)=C(C(F)(F)F)C=C1N1N=NC2=C1C(C=C(C=C1)C(C=N3)=CC=C3OC)=C1NC2=O Chemical compound CN(CC1)CCN1C(C=C1)=C(C(F)(F)F)C=C1N1N=NC2=C1C(C=C(C=C1)C(C=N3)=CC=C3OC)=C1NC2=O KYKNTEXSDOHADZ-UHFFFAOYSA-N 0.000 description 2
- VMMREKSYABLHJK-UHFFFAOYSA-N COC(C=C(C=C1)N2N=NC3=C2C(C=C(C=C2)C(C=N4)=CC=C4OC)=C2NC3=O)=C1N1CCNCC1 Chemical compound COC(C=C(C=C1)N2N=NC3=C2C(C=C(C=C2)C(C=N4)=CC=C4OC)=C2NC3=O)=C1N1CCNCC1 VMMREKSYABLHJK-UHFFFAOYSA-N 0.000 description 2
- NVODNHXYZKCHKJ-UHFFFAOYSA-N COC(N=C1)=CC=C1C(C=C1)=CC(C2=C3N=NN2C(C=C2)=CC(C(F)(F)F)=C2N2CCN(CCO)CC2)=C1N(CCO)C3=O Chemical compound COC(N=C1)=CC=C1C(C=C1)=CC(C2=C3N=NN2C(C=C2)=CC(C(F)(F)F)=C2N2CCN(CCO)CC2)=C1N(CCO)C3=O NVODNHXYZKCHKJ-UHFFFAOYSA-N 0.000 description 2
- XUCKDROCCGFJIV-UHFFFAOYSA-N COC(N=C1)=CC=C1C(C=C1)=CC(C2=C3N=NN2C(C=C2)=CC(Cl)=C2N2CCNCC2)=C1NC3=O Chemical compound COC(N=C1)=CC=C1C(C=C1)=CC(C2=C3N=NN2C(C=C2)=CC(Cl)=C2N2CCNCC2)=C1NC3=O XUCKDROCCGFJIV-UHFFFAOYSA-N 0.000 description 2
- UMBRJLNFXLRAOS-UHFFFAOYSA-N COC(N=C1)=CC=C1C(C=C1)=CC(C2=C3N=NN2C2=CC=CC4=CC=CC=C24)=C1NC3=O Chemical compound COC(N=C1)=CC=C1C(C=C1)=CC(C2=C3N=NN2C2=CC=CC4=CC=CC=C24)=C1NC3=O UMBRJLNFXLRAOS-UHFFFAOYSA-N 0.000 description 2
- XANATEBQMKZRRK-UHFFFAOYSA-N COC1=CC=C(CN(C(C=CC(C(C=N2)=CC=C2OC)=C2)=C2C2=C3N=NN2C(C=C2)=CC(OC)=C2N2CCNCC2)C3=O)C=C1 Chemical compound COC1=CC=C(CN(C(C=CC(C(C=N2)=CC=C2OC)=C2)=C2C2=C3N=NN2C(C=C2)=CC(OC)=C2N2CCNCC2)C3=O)C=C1 XANATEBQMKZRRK-UHFFFAOYSA-N 0.000 description 2
- 101100468996 Caenorhabditis elegans riok-2 gene Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- IDHJIFHBNRNFHZ-UHFFFAOYSA-N O=C1NC(C=CC=C2)=C2C2=C1N=NN2C(C=C1)=CC=C1N1CCNCC1 Chemical compound O=C1NC(C=CC=C2)=C2C2=C1N=NN2C(C=C1)=CC=C1N1CCNCC1 IDHJIFHBNRNFHZ-UHFFFAOYSA-N 0.000 description 2
- 108010016076 Octreotide Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 2
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 2
- 229960001097 amifostine Drugs 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229960004242 dronabinol Drugs 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 229960004177 filgrastim Drugs 0.000 description 2
- 229960002258 fulvestrant Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 2
- 108700020746 histrelin Proteins 0.000 description 2
- 229960002193 histrelin Drugs 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 229960003685 imatinib mesylate Drugs 0.000 description 2
- 125000001967 indiganyl group Chemical group [H][In]([H])[*] 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 2
- 229960002700 octreotide Drugs 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 2
- 229960005079 pemetrexed Drugs 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229960002139 pilocarpine hydrochloride Drugs 0.000 description 2
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- VSGPVHSTVTXREH-UHFFFAOYSA-N quinolin-4-one Chemical compound C1=CC=C[C]2C(=O)C=CN=C21 VSGPVHSTVTXREH-UHFFFAOYSA-N 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000028710 ribosome assembly Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229960002812 sunitinib malate Drugs 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 2
- 229960005026 toremifene Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- VESKBLGTHHPZJF-QNWVGRARSA-N (2s)-2-amino-5-[[(2r)-2-amino-3-[2-[bis[bis(2-chloroethyl)amino]phosphoryloxy]ethylsulfonyl]propanoyl]-[(r)-carboxy(phenyl)methyl]amino]-5-oxopentanoic acid Chemical compound ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](N)C(=O)N(C(=O)CC[C@H](N)C(O)=O)[C@@H](C(O)=O)C1=CC=CC=C1 VESKBLGTHHPZJF-QNWVGRARSA-N 0.000 description 1
- ZBVJFYPGLGEMIN-OYLNGHKZSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-( Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1.C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 ZBVJFYPGLGEMIN-OYLNGHKZSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- OMJKFYKNWZZKTK-POHAHGRESA-N (5z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- ZGMJYTYLTJFNCS-VQYXCCSOSA-N (e)-but-2-enedioic acid;1-[4-(2-hydroxy-3-quinolin-5-yloxypropyl)piperazin-1-yl]-2,2-diphenylethanone Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.C=1C=CC2=NC=CC=C2C=1OCC(O)CN(CC1)CCN1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC2=NC=CC=C2C=1OCC(O)CN(CC1)CCN1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 ZGMJYTYLTJFNCS-VQYXCCSOSA-N 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical compound C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- PMZDQRJGMBOQBF-UHFFFAOYSA-N 1H-quinolin-4-one Natural products C1=CC=C2C(O)=CC=NC2=C1 PMZDQRJGMBOQBF-UHFFFAOYSA-N 0.000 description 1
- ROZCIVXTLACYNY-UHFFFAOYSA-N 2,3,4,5,6-pentafluoro-n-(3-fluoro-4-methoxyphenyl)benzenesulfonamide Chemical compound C1=C(F)C(OC)=CC=C1NS(=O)(=O)C1=C(F)C(F)=C(F)C(F)=C1F ROZCIVXTLACYNY-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- ZAPMTSHEXFEPSD-UHFFFAOYSA-N 4-(2-chloroethyl)morpholine Chemical compound ClCCN1CCOCC1 ZAPMTSHEXFEPSD-UHFFFAOYSA-N 0.000 description 1
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- HFEKDTCAMMOLQP-RRKCRQDMSA-N 5-fluorodeoxyuridine monophosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(F)=C1 HFEKDTCAMMOLQP-RRKCRQDMSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- MKBLHFILKIKSQM-UHFFFAOYSA-N 9-methyl-3-[(2-methyl-1h-imidazol-3-ium-3-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;chloride Chemical compound Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 MKBLHFILKIKSQM-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 108010019673 Darbepoetin alfa Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101000754911 Homo sapiens Serine/threonine-protein kinase RIO3 Proteins 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 102000040104 IAP family Human genes 0.000 description 1
- 108091069885 IAP family Proteins 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 238000003749 KINOMEscan Methods 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 241000408529 Libra Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- BKLZHLLIWKYAJT-MGONKNPOSA-N P(=O)(O)(O)OC1=CC2=C([C@H]3CC[C@@]4(C(CC[C@H]4[C@@H]3CC2)OC(CCCC)=O)C)C=C1 Chemical compound P(=O)(O)(O)OC1=CC2=C([C@H]3CC[C@@]4(C(CC[C@H]4[C@@H]3CC2)OC(CCCC)=O)C)C=C1 BKLZHLLIWKYAJT-MGONKNPOSA-N 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100022109 Serine/threonine-protein kinase RIO3 Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108010011834 Streptolysins Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 244000297179 Syringa vulgaris Species 0.000 description 1
- 235000004338 Syringa vulgaris Nutrition 0.000 description 1
- 108700011582 TER 286 Proteins 0.000 description 1
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101800001530 Thymosin alpha Proteins 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 102000000887 Transcription factor STAT Human genes 0.000 description 1
- 108050007918 Transcription factor STAT Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- XJXKGUZINMNEDK-GPJOBVNKSA-L [(4r,5r)-5-(aminomethyl)-2-propan-2-yl-1,3-dioxolan-4-yl]methanamine;platinum(2+);propanedioate Chemical compound [Pt+2].[O-]C(=O)CC([O-])=O.CC(C)C1O[C@H](CN)[C@@H](CN)O1 XJXKGUZINMNEDK-GPJOBVNKSA-L 0.000 description 1
- BBWXLCKRYRQQPL-ZBRFXRBCSA-N [(8r,9s,13s,14s,17s)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] dihydrogen phosphate Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 BBWXLCKRYRQQPL-ZBRFXRBCSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- DUYNJNWVGIWJRI-LJAQVGFWSA-N acolbifene Chemical compound C1=CC([C@H]2C(=C(C3=CC=C(O)C=C3O2)C)C=2C=CC(O)=CC=2)=CC=C1OCCN1CCCCC1 DUYNJNWVGIWJRI-LJAQVGFWSA-N 0.000 description 1
- 229950002421 acolbifene Drugs 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960004343 alendronic acid Drugs 0.000 description 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 1
- 229960003235 allopurinol sodium Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- 229960001372 aprepitant Drugs 0.000 description 1
- 229940115115 aranesp Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- UVJYAKBJSGRTHA-ZCRGAIPPSA-N arglabin Chemical compound C1C[C@H]2C(=C)C(=O)O[C@@H]2[C@@H]2C(C)=CC[C@]32O[C@]31C UVJYAKBJSGRTHA-ZCRGAIPPSA-N 0.000 description 1
- UVJYAKBJSGRTHA-UHFFFAOYSA-N arglabin Natural products C1CC2C(=C)C(=O)OC2C2C(C)=CCC32OC31C UVJYAKBJSGRTHA-UHFFFAOYSA-N 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
- 229950004810 atamestane Drugs 0.000 description 1
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 description 1
- 229950010993 atrasentan Drugs 0.000 description 1
- MXWJVTOOROXGIU-UHFFFAOYSA-N atrazine Chemical compound CCNC1=NC(Cl)=NC(NC(C)C)=N1 MXWJVTOOROXGIU-UHFFFAOYSA-N 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229960004648 betamethasone acetate Drugs 0.000 description 1
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 description 1
- 229960005354 betamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 229960004395 bleomycin sulfate Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- RJTANRZEWTUVMA-UHFFFAOYSA-N boron;n-methylmethanamine Chemical compound [B].CNC RJTANRZEWTUVMA-UHFFFAOYSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 1
- 229960001921 calcium levofolinate Drugs 0.000 description 1
- KVUAALJSMIVURS-QNTKWALQSA-L calcium;(2s)-2-[[4-[[(6s)-2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioate Chemical compound [Ca+2].C([C@@H]1N(C=O)C=2C(=O)N=C(NC=2NC1)N)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-QNTKWALQSA-L 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 150000001768 cations Chemical group 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000011950 custard Nutrition 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 108700025485 deslorelin Proteins 0.000 description 1
- 229960005408 deslorelin Drugs 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 1
- 125000005048 dihydroisoxazolyl group Chemical group O1N(CC=C1)* 0.000 description 1
- 125000005049 dihydrooxadiazolyl group Chemical group O1N(NC=C1)* 0.000 description 1
- 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 description 1
- 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 description 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 125000005058 dihydrotriazolyl group Chemical group N1(NNC=C1)* 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- YGLLICRFEVEWOZ-UHFFFAOYSA-L disodium;3-carboxy-1-[(3-carboxy-2-oxidonaphthalen-1-yl)methyl]naphthalen-2-olate Chemical compound [Na+].[Na+].C1=CC=C2C(CC3=C4C=CC=CC4=CC(=C3O)C([O-])=O)=C(O)C(C([O-])=O)=CC2=C1 YGLLICRFEVEWOZ-UHFFFAOYSA-L 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
- 229960005178 doxylamine Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000002359 drug metabolite Substances 0.000 description 1
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
- 229960004199 dutasteride Drugs 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960003265 epirubicin hydrochloride Drugs 0.000 description 1
- 229950006835 eptaplatin Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000002834 estrogen receptor modulator Substances 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 229960004931 histamine dihydrochloride Drugs 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- ZFEZZRFBMNCXLQ-UHFFFAOYSA-K holmium(3+);phosphate Chemical compound [Ho+3].[O-]P([O-])([O-])=O ZFEZZRFBMNCXLQ-UHFFFAOYSA-K 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- DQOCFCZRZOAIBN-WZHZPDAFSA-L hydroxycobalamin Chemical compound O.[Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O DQOCFCZRZOAIBN-WZHZPDAFSA-L 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000003674 kinase activity assay Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
- 229960002367 lasofoxifene Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 229960003918 levothyroxine sodium Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 1
- 229960000423 loxapine Drugs 0.000 description 1
- 108010078259 luprolide acetate gel depot Proteins 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 229960005321 mecobalamin Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 description 1
- 229950011129 minodronic acid Drugs 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 1
- 229950010159 nemorubicin Drugs 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- XHWRWCSCBDLOLM-UHFFFAOYSA-N nolatrexed Chemical compound CC1=CC=C2NC(N)=NC(=O)C2=C1SC1=CC=NC=C1 XHWRWCSCBDLOLM-UHFFFAOYSA-N 0.000 description 1
- 229950000891 nolatrexed Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960000770 ondansetron hydrochloride Drugs 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- OLDRWYVIKMSFFB-SSPJITILSA-N palonosetron hydrochloride Chemical compound Cl.C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 OLDRWYVIKMSFFB-SSPJITILSA-N 0.000 description 1
- 229960003359 palonosetron hydrochloride Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- MPNNOLHYOHFJKL-UHFFFAOYSA-N peroxyphosphoric acid Chemical compound OOP(O)(O)=O MPNNOLHYOHFJKL-UHFFFAOYSA-N 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 108010076042 phenomycin Proteins 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 239000003197 protein kinase B inhibitor Substances 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 229950007649 ranpirnase Drugs 0.000 description 1
- 108010061338 ranpirnase Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 190014017285 satraplatin Chemical compound 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000849 selective androgen receptor modulator Substances 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 229950009921 seocalcitol Drugs 0.000 description 1
- LVLLALCJVJNGQQ-ZCPUWASBSA-N seocalcitol Chemical compound C1(/[C@H]2CC[C@@H]([C@@]2(CCC1)C)[C@H](C)/C=C/C=C/C(O)(CC)CC)=C/C=C1/C[C@H](O)C[C@@H](O)C1=C LVLLALCJVJNGQQ-ZCPUWASBSA-N 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- PTJRZVJXXNYNLN-UHFFFAOYSA-M sodium;2h-pyrazolo[3,4-d]pyrimidin-1-id-4-one Chemical compound [Na+].[O-]C1=NC=NC2=C1C=NN2 PTJRZVJXXNYNLN-UHFFFAOYSA-M 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229960002613 tamsulosin Drugs 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- LCZVKKUAUWQDPX-UHFFFAOYSA-N tert-butyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]ethyl]amino]acetate Chemical compound CC(=O)OC1=CC=CC=C1CN(CC(=O)OC(C)(C)C)CCN(CC(=O)OC(C)(C)C)CC1=CC=CC=C1OC(C)=O LCZVKKUAUWQDPX-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 1
- 229950009158 tipifarnib Drugs 0.000 description 1
- ORYDPOVDJJZGHQ-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=CC2=[N+]([O-])C(N)=N[N+]([O-])=C21 ORYDPOVDJJZGHQ-UHFFFAOYSA-N 0.000 description 1
- 229950002376 tirapazamine Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 229940043263 traditional drug Drugs 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960000294 triptorelin pamoate Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- KIGCDEJCMKDBHU-NIQQUOCOSA-K ukrain Chemical compound [OH-].[OH-].[OH-].C([C@H](O)[C@@H]1C2=CC=C3OCOC3=C2C2)C3=CC=4OCOC=4C=C3[C@H]1[N+]2(C)CCNP(=S)(NCC[N+]1(C)[C@@H]2C3=CC=4OCOC=4C=C3C[C@H](O)[C@@H]2C2=CC=C3OCOC3=C2C1)NCC[N+]1(C)[C@@H]2C3=CC(OCO4)=C4C=C3C[C@H](O)[C@@H]2C2=CC=C3OCOC3=C2C1 KIGCDEJCMKDBHU-NIQQUOCOSA-K 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229950005577 vesnarinone Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 229960000744 vinpocetine Drugs 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种具有式Ⅰ所示结构的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子及其药物组合物和应用。本发明涉及的化合物及其药学上可接受的盐对RIOK2蛋白酶产生抑制作用,可以有效抑制多种肿瘤细胞的生长,可用于制备抗肿瘤药物。
Description
技术领域
本发明涉及化学医药技术领域,具体涉及一种含氮并杂环类化合物及其药用组合物和应用。
背景技术
恶性肿瘤(癌症)是一类重大的恶性疾病,已成为人类最为致命的“杀手”。针对癌症的常规治疗方法,包括放疗、化疗、手术切除、其他各种各样的治疗途径以及药物的发现等虽对癌症患者带来了希望,但往往存在不少弊端,包括副作用大,治疗效果不佳,肿瘤预后复发,转移等。因此,迫切需要新的治疗技术来解决这类瓶颈问题。个体化治疗和靶向治疗是近年来被看作是突破目前癌症治疗瓶颈的希望所在。
肿瘤分子靶向治疗是基于对肿瘤生长密切相关的关键分子通过化学或生物学手段选择性杀伤肿瘤细胞的一种治疗方法。具有特异性高,选择性强,毒副作用较轻等特点;联合应用时,它可加强传统化疗、放疗的疗效,减少术后复发。以伊马替尼甲磺酸盐(STI571)(Novartis,2001),吉非替尼(ZD1839)(AstraZeneca,2003),厄罗替尼(OSI774)(Genentech and OSIP,2004),索拉菲尼对甲苯磺酸盐(Bay 43-9006)(Bayer and Onyx,2005),舒尼替尼苹果酸盐(SU11248)(Pfizer,2006)以及达沙替尼(BMS-354825)(Bristol-Myers Squibb,2006)为代表的靶向药物为肿瘤化疗开创了一个新时代。肿瘤靶向治疗在短短几年内得到了迅速发展。肿瘤靶向治疗的出现已对传统给药观念和模式构成冲击,例如,因毒副作用小靶向药物在I期临床试验中往往无法达到剂量限制性毒性和最大耐受剂量;用靶向治疗药物时无需用最大耐受剂量即可达到满意疗效。肿瘤靶向治疗是肿瘤治疗的热点和发展趋势。
针对癌症发生发展过程中发挥重要调控作用以及重要功能的一些关键蛋白,发展小分子抑制剂,进行靶向调控,在治疗癌症等疾病中具有特殊的应用。
RIO蛋白激酶(RIOKs)是一类进化上比较保守的非典型蛋白激酶,广泛存在于所有真核生物以及大部分古细菌和原核生物中。目前已发现包括三种亚型,其中RIOK1,RIOK2被发现存在于所有真核生物中,而在一些较高等的真核生物中,还存在RIOK3。这类激酶是在40s核糖体前体的组成成分,并且在40S核糖体生成过程中的不同阶段分别发挥其不同功能,例如RIOK1或RIOK2的缺失将阻止40S核糖体的成熟。RIOKs虽然具有蛋白激酶的结构域,但缺乏其他真核蛋白激酶中所存在的底物结合区域,包括活化环。研究表明,RIOKs的主要功能是作为ATP水解酶来发挥作用。RIOK2在多种类型的癌症中呈现高表达。在非小细胞肺癌患者中,RIOK2的高表达与最终结果的恶性程度呈现明显的相关性。细胞周期的正常进行依赖于蛋白的翻译,但RIOK2是简单的通过高表达来增强核糖体的组装能力从而促进蛋白合成,还是获得了其他的促进核糖体组装的致癌性功能还有待深入研究。目前已有一些证据表明,RIOK1和RIOK2能促进细胞增殖和存活,其表达与致癌的AKT信号通路相关。RIOK1和RIOK2可能还在PI3Ks激酶和包括EGFR在内的受体酪氨酸激酶等下游信号通路中发挥作用。
鉴于RIOK2在多种类型癌症中高表达,针对RIOK2发展小分子抑制剂,有助于了解RIOK家族在细胞中的功能,并有望发展新的靶向抗肿瘤药物。2019年牛津大学、礼来公司、巴西西亚瓦斯城市大学的研究人员合作报道了小分子抑制剂与人类RIOK2结合的晶体结构。为开发选择性RIOK2小分子抑制剂奠定了基础。但他们所报道的小分子抑制剂对RIOK2的抑制活性相对较弱。因此,对于具有新骨架、高活性的RIOK家族小分子抑制剂开发,具有迫切的需要。
发明内容
针对上述问题,本发明提供了一种新的含氮并杂环类化合物,该类化合物能够高活性地抑制RIOK2蛋白激酶的活性,从而能够抑制多种肿瘤细胞的增殖。
具体技术方案如下:
具有式(Ⅰ)所示结构的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子:
其中,
A1、A2、B1、B2、D和E分别独立地选自:N、CR2;
X任选自:O、S、NR3;
Ar1和Ar2分别独立地选自:取代或未取代的C6~C10芳基、取代或未取代的5~10元杂芳基;
R1任选自:H、C1~C6烷基、C3~C6环烷基、3~6元杂环烷基、C1~C8酰基、磺酰基、C6~C18芳基、C6~C18芳基取代的C1~C6烷基、5~18元杂芳基;当R1不为氢时,所述R1独立任选地被1个或多个R4取代;
各R2分别独立地选自:H、卤素、C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、C1~C18烷胺基、氨基、羟基、氰基、硝基、酯基、酰胺基、磺酰基、磺酰氨基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基、5~18元杂芳基;当R2选自C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、C1~C18烷胺基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基或5~18元杂芳基时,所述R2独立任选地被1个或多个R4取代;
R3任选自:H、C1~C18烷基、C6~C18芳基取代的C1~C18烷基、C3~C18环烷基、C6~C18芳基取代的C3~C18环烷基、C1~C8酰基、磺酰基;当R3不为氢时,所述R1独立任选地被1个或多个R4取代;
各R4分别独立地选自:H、羟基、氨基、氰基、硝基、卤素、C1~C6烷氧基、C1~C6烷基。
在其中一些实施例中,Ar1和Ar2分别独立地任选自:苯基、噻唑基、呋喃基、吡咯基、吡唑基、咪唑基、吡啶基、嘧啶基、吲哚基、苯并噻唑基、苯并咪唑基、苯并呋喃基;所述Ar1和Ar2分别独立任选地被一个或多个取代基取代,或者未被取代基取代。
在其中一些实施例中,所述的含氮并杂环类化合物具有式(Ⅱ)或者式(III)所示结构:
其中,X1、X2、X3、X4、X5分别独立地选自:N、CR5;
X6、X7、X8、X9和X10分别独立地选自:N、CR6、CR;并且X6、X7、X8、X9和X10中至少有一个选自CR;
Y选自:O、S、NR3;
各R5分别独立地选自:H、卤素、C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、C1~C18烷胺基、氨基、羟基、氰基、硝基、酯基、酰胺基、磺酰基、磺酰氨基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基、5~18元杂芳基;当R5选自C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、C1~C18烷胺基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基或5~18元杂芳基时,所述R5独立任选地被1个或多个R4取代;
各R6分别独立地任选自:H、卤素、C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、C1~C18烷胺基、氨基、羟基、氰基、硝基、酯基、酰胺基、磺酰基、磺酰氨基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基、5~18元杂芳基;当R6选自C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、C1~C18烷胺基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基或5~18元杂芳基时,所述R6独立任选地被1个或多个R4取代;
各R7,R8分别独立地任选自:H、C1~C8烷基,羟基取代的C1~C8烷基,C1~C8烷氧基取代的C1~C8烷基、C3~C8环烷基、3~18元杂环烷基、C1~C8酰基、烯基酰基、磺酰基、5~18元杂芳基;或者R7、R8与和其相连的N原子一起形成取代或者未取代的3-10元杂环基,或者R7、R8与和其相连的N原子一起形成取代或者未取代的5~10元杂芳基;
n选自:0-6之间的整数;
各R9分别独立地任选自:H、卤素、C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、C1~C18烷胺基、氨基、羟基、氰基、硝基、酯基、乙酰基、丙酰基、丁酰基、酰胺基、磺酰基、磺酰氨基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基、5~18元杂芳基;当R9选自C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、C1~C18烷胺基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基或5~18元杂芳基时,所述R9独立任选地被1个或多个R4取代。
在其中一些实施例中,所述的含氮并杂环类化合物具有式(IV)或(V)所示结构:
在其中一些实施例中,其具有式(VI)或(VII)所示结构:
在其中一些实施例中,其具有式(VIII)或(IX)所示结构:
在其中一些实施例中,各R7,R8分别独立地任选自:H、C1~C8烷基,羟基取代的C1~C8烷基,C1~C8烷氧基取代的C1~C8烷基、C3~C8环烷基、3~18元杂环烷基、C1~C8酰基、烯基酰基、磺酰基、5~18元杂芳基;或者R7、R8与和其相连的N原子一起形成如下结构:
m,n分别独立地选自:0-6之间的整数;
各R9分别独立地任选自:H、卤素、C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、C1~C18烷胺基、氨基、羟基、氰基、硝基、酯基、乙酰基、丙酰基、丁酰基、酰胺基、磺酰基、磺酰氨基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基、5~18元杂芳基;当R9选自C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、C1~C18烷胺基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基或5~18元杂芳基时,所述R9独立任选地被1个或多个R4取代;
各R10分别独立地任选自:H、卤素、C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、C1~C18烷胺基、氨基、羟基、氰基、硝基、酯基、乙酰基、丙酰基、丁酰基、酰胺基、磺酰基、磺酰氨基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基、5~18元杂芳基;当R10选自C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、C1~C18烷胺基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基或5~18元杂芳基时,所述R10独立任选地被1个或多个R11取代;
各R11分别独立地任选自:H、羟基、氨基、氰基、硝基、卤素、C1~C6烷氧基、C1~C6烷基、磷酸基、二甲基氨基。
在其中一些实施例中,R选自:
在其中一些实施例中,各R9分别独立地任选自:H、卤素、C1~C6烷基、C3~C8环烷基、3~8元杂环烷基、C1~C6烷氧基、C1~C6烷胺基、氨基、羟基、氰基、硝基、酯基、酰胺基、磺酰基、磺酰氨基、C6~C10芳基、C6~C10芳基取代的C1~C10烷基、5~10元杂芳基;当R9选自C1~C6烷基、C3~C8环烷基、3~8元杂环烷基、C1~C6烷氧基、C1~C6烷胺基、C6~C10芳基、C6~C10芳基取代的C1~C6烷基或5~10元杂芳基时,所述R9独立任选地被1个或多个R4取代;
各R10分别独立地任选自:H、C1~C6烷基、C3~C8环烷基、3~8元杂环烷基、C1~C6烷氧基、C1~C6烷胺基、氨基、羟基、氰基、硝基、酯基、乙酰基、丙酰基、丁酰基、酰胺基、磺酰基、磺酰氨基、C6~C10芳基、C6~C10芳基取代的C1~C10烷基、5~10元杂芳基;当R10选自C1~C6烷基、C3~C8环烷基、3~8元杂环烷基、C1~C6烷氧基、C1~C6烷胺基、C6~C10芳基、C6~C10芳基取代的C1~C6烷基或5~10元杂芳基时,所述R10独立任选地被1个或多个R11取代。
在其中一些实施例中,H、C1~C3烷基;
各R10分别独立地任选自:H、C1~C3烷基、R11取代的C1~C3烷基;R11选自:羟基、二甲基氨基。
在其中一些实施例中,各R5分别独立地任选自:H、卤素、C1~C6烷基、C3~C8环烷基、3~8元杂环烷基、C1~C6烷氧基、C1~C6烷胺基、氨基、羟基、氰基、硝基、酯基、酰胺基、磺酰基、磺酰氨基、C6~C10芳基、C6~C10芳基取代的C1~C6烷基、5~10元杂芳基;当R5选自C1~C6烷基、C3~C8环烷基、3~8元杂环烷基、C1~C6烷氧基、C1~C6烷胺基、C6~C10芳基、C6~C10芳基取代的C1~C6烷基或5~10元杂芳基时,所述R5独立任选地被1个或多个R4取代。
在其中一些实施例中,各R5分别独立地任选自:H、C1~C6烷基、C1~C6烷氧基、羟基。
在其中一些实施例中,各R5分别独立地任选自:甲氧基、乙氧基。
在其中一些实施例中,各R6分别独立地任选自:H、卤素、C1~C6烷基、C3~C8环烷基、3~8元杂环烷基、C1~C6烷氧基、C1~C6烷胺基、氨基、羟基、氰基、硝基、酯基、酰胺基、磺酰基、磺酰氨基、C6~C10芳基、C6~C10芳基取代的C1~C6烷基、5~10元杂芳基;当R6选自C1~C6烷基、C3~C8环烷基、3~8元杂环烷基、C1~C6烷氧基、C1~C6烷胺基、C6~C10芳基、C6~C10芳基取代的C1~C6烷基或5~10元杂芳基时,所述R6独立任选地被1个或多个R4取代。
在其中一些实施例中,各R6分别独立地任选自:H、卤素、C1~C6烷基、C1~C6烷氧基、三氟甲基;并且X6、X7、X8、X9和X10中至少有一个选自CR6,至少有一个R6不为氢。
在其中一些实施例中,各R6分别独立地任选自:H、F、Cl、甲基、三氟甲基、甲氧基;并且X6、X7、X8、X9和X10中至少有一个选自CR6,至少有一个R6不为氢。
在其中一些实施例中,A1和B1为N;A2、B2、D和E为CR2;X为O。
在其中一些实施例中,R1任选自:H、C1~C6烷基、羟基取代的C1~C6烷基、对甲氧基苄基。
在其中一些实施例中,R1任选自:H、甲基、乙基、丙基、异丙基,羟乙基、对甲氧基苄基。
本发明还提供了上述的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子的应用。
具体技术方案如下:
上述的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子在制备RIOK2抑制剂中的应用。
上述的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子在制备预防或者治疗肿瘤的药物中的应用。
在其中一些实施例中,所述肿瘤为:非小细胞肺癌、小细胞肺癌、肺腺癌、肺鳞癌、胰腺癌、乳腺癌、前列腺癌、肝癌、皮肤癌、上皮细胞癌、胃肠间质瘤、白血病、组织细胞性淋巴癌、鼻咽癌、胶质瘤、骨肉瘤、胃癌、皮肤鳞癌、卵巢癌。
本发明还提供了一种预防或者治疗肿瘤的药用组合物。
具体技术方案如下:
一种预防或者治疗肿瘤的药用组合物,由活性成分和药学上可接受的辅料制备得到,所述活性成分包括上述的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子。
本发明的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子,是一类新颖的具有高活性、高选择性的RIOK2抑制剂,并对RIOK家族其他蛋白激酶产生抑制作用,可以有效抑制多种肿瘤细胞的生长,可用于制备抗肿瘤药物,可用于治疗人类及其它哺乳动物的肿瘤等过渡增殖性疾病。
具体实施方式
本发明所述化合物中,当任何变量(例如R等)在任何组分中出现超过一次,则其每次出现的定义独立于其它每次出现的定义。同样,允许取代基及变量的组合,只要这种组合使化合物稳定。自取代基划入环系统的线表示所指的键可连接到任何能取代的环原子上。如果环系统为多环,其意味着这种键仅连接到邻近环的任何适当的碳原子上。要理解本领域普通技术人员可选择本发明化合物的取代基及取代型式而提供化学上稳定的并可通过本领域技术和下列提出的方法自可容易获得的原料容易的合成的化合物。如果取代基自身被超过一个基团取代,应理解这些基团可在相同碳原子上或不同碳原子上,只要使结构稳定。
本文所用术语“烷基”意指包括具有特定碳原子数目的支链的和直链的饱和脂肪烃基。例如,“C1-C6烷基”中“C1-C6”的定义包括以直链或支链排列的具有1、2、3、4、5或6个碳原子的基团。例如,“C1-C6烷基”具体包括甲基、乙基、正丙基、异丙基、正丁基、叔丁基、异丁基、戊基、己基。术语“环烷基”指具有特定碳原子数目的单环饱和脂肪烃基。例如“环烷基”包括环丙基、环丁基、环戊基或环己基等。术语“烷氧基”指具有-O-烷基结构的基团,如-OCH3、-OCH2CH3、-OCH2CH2CH3、-O-CH2CH(CH3)2、-OCH2CH2CH2CH3、-O-CH(CH3)2等。术语“杂环烷基”为饱和或部分不饱和的单环或多环环状取代基,其中一个或多个环原子选自N、O或S(O)m(其中m是0-2的整数)的杂原子,其余环原子为碳,例如:吗啉基、哌啶基、四氢吡咯基、吡咯烷基、二氢咪唑基、二氢异噁唑基、二氢异噻唑基、二氢噁二唑基、二氢噁唑基、二氢吡嗪基、二氢吡唑基、二氢吡啶基、二氢嘧啶基、二氢吡咯基、二氢四唑基、二氢噻二唑基、二氢噻唑基、二氢噻吩基、二氢三唑基、二氢氮杂环丁烷基、四氢呋喃基、四氢噻吩基等,及其N-氧化物,杂环取代基的连接可通过碳原子或通过杂原子实现。术语“杂芳基”指含有1个或多个选自O、N或S的杂原子的芳香环,本发明范围内的杂芳基包括但不限于:喹啉基、吡唑基、吡咯基、噻吩基、呋喃基、吡啶基、嘧啶基、吡嗪基、三氮唑基、咪唑基、噁唑基、异噁唑基、哒嗪基;“杂芳基”也理解为包括任何含有氮的杂芳基的N-氧化物衍生物。
正如本领域技术人员所理解的,本文中所用“卤素”(“halo”)或“卤”意指氯、氟、溴和碘。
除非另有定义,烷基、环烷基、芳基、杂芳基和杂环烷基取代基可为未被取代的或取代的。例如,C1-C6烷基可被一个、两个或三个选自OH、卤素、烷氧基、二烷基氨基或杂环基例如吗啉基、哌啶基等的取代基取代。
本发明包括式Ⅰ-IX化合物的游离形式,也包括其药学上可接受的盐及立体异构体。本文中一些特定的示例性化合物为胺类化合物的质子化了的盐。术语“游离形式”指以非盐形式的胺类化合物。包括在内的药学上可接受盐不仅包括本文所述特定化合物的示例性盐,也包括所有式Ⅰ-IX化合物游离形式的典型的药学上可接受的盐。可使用本领域已知技术分离所述化合物特定盐的游离形式。例如,可通过用适当的碱稀水溶液例如NaOH稀水溶液、碳酸钾稀水溶液、稀氨水及碳酸氢钠稀水溶液处理该盐使游离形式再生。游离形式在某些物理性质例如在极性溶剂中溶解度上与其各自盐形式多少有些区别,但是为发明的目的这种酸盐及碱盐在其它药学方面与其各自游离形式相当。
可通过常规化学方法自含有碱性部分或酸性部分的本发明化合物合成本发明的药学上可接受的盐。通常,通过离子交换色谱或通过游离碱和化学计算量或过量的所需盐形式的无机或有机酸在适当溶剂或多种溶剂的组合中反应制备碱性化合物的盐。类似的,通过和适当的无机或有机碱反应形成酸性化合物的盐。
因此,本发明化合物的药学上可接受的盐包括通过碱性本发明化合物和无机或有机酸反应形成的本发明化合物的常规无毒盐。例如,常规的无毒盐包括得自无机酸例如盐酸、氢溴酸、硫酸、氨基磺酸、磷酸、硝酸等的盐,也包括自有机酸例如乙酸、丙酸、琥珀酸、乙醇酸、硬脂酸、乳酸、苹果酸、酒石酸、柠檬酸、抗坏血酸、扑酸、马来酸、羟基马来酸、苯乙酸、谷氨酸、苯甲酸、水杨酸、对氨基苯磺酸、2一乙酰氧基一苯甲酸、富马酸、甲苯磺酸、甲磺酸、乙烷二磺酸、草酸、羟乙基磺酸、三氟乙酸等制备的盐。
如果本发明化合物为酸性的,则适当的“药学上可接受的盐”指通过药学上可接受的无毒碱包括无机碱及有机碱制备的盐.得自无机碱的盐包括铝盐、铵盐、钙盐、铜盐、铁盐、亚铁盐、锂盐、镁盐、锰盐、亚锰盐、钾盐、钠盐、锌盐等。特别优选铵盐、钙盐、镁盐、钾盐和钠盐。得自药学上可接受的有机无毒碱的盐,所述碱包括伯胺、仲胺和叔胺的盐,取代的胺包括天然存在的取代胺、环状胺及碱性离子交换树脂例如精氨酸、甜菜碱、咖啡因、胆碱、N,N'-二苄基乙二胺、二乙胺、2一二乙基氨基乙醇、2一二甲基氨基乙醇、氨基乙醇、乙醇胺、乙二胺、N一乙基吗啉、N一乙基哌啶、葡萄糖胺、氨基葡萄糖、组氨酸、羟钴胺、异丙基胺、赖氨酸、甲基葡萄糖胺、吗啉、哌嗪,哌啶、呱咤、多胺树脂、普鲁卡因、嘌呤、可可碱、三乙胺、三甲胺、三丙胺、氨基丁三醇等。
Berg等,“Pharmaceutical Salts,”J.Pharm.Sci.’1977:66:1-19更详细描述了上文所述药学上可接受的盐及其它典型的药学上可接受的盐的制备。
由于在生理条件下化合物中脱质子化的酸性部分例如竣基可为阴离子的,而这种带有的电荷然后可被内部带有阳离子的质子化了的或烷基化的碱性部分例如四价氮原子平衡抵消,所以应注意本发明化合物是潜在的内盐或两性离子。
在一个实施方案中,本申请提供了一种利用具有式Ⅰ-IX的化合物及其药学可接受的盐治疗人或其它哺乳动物肿瘤等过渡增殖性疾病或症状。
在一个实施方案中,本申请的化合物及其药学可接受的盐可以用于治疗或控制非小细胞肺癌、小细胞肺癌、肺腺癌、肺鳞癌、胰腺癌、乳腺癌、前列腺癌、肝癌、皮肤癌、上皮细胞癌、胃肠间质瘤、白血病、组织细胞性淋巴癌、鼻咽癌、胶质瘤、骨肉瘤、胃癌、皮肤鳞癌、卵巢癌等过渡增殖性疾病。
药物代谢物及前药
本申请所涉及的化合物及其药学可接受的盐的代谢产物,以及可以在体内转变为本申请所涉及的化合物及其药学可接受的盐的结构的前药,也包含在本申请的权利要求中。
联合用药
式Ⅰ-IX化合物可以与已知的治疗或改进相似病状的其它药物联用。联合给药时,原来药物的给药方式&剂量保持不变,而同时或随后服用式Ⅰ-IX化合物。当式Ⅰ-IX化合物与其它一种或几种药物同时服用时,优选使用同时含有一种或几种已知药物和式I化合物的药用组合物。药物联用也包括在重叠的时间段服用式Ⅰ-IX化合物与其它一种或几种已知药物。当式Ⅰ-IX化合物与其它一种或几种药物进行药物联用时,式Ⅰ-IX化合物或已知药物的剂量可能比它们单独用药时的剂量较低。
可以与式Ⅰ-IX化合物进行药物联用的药物或活性成分包括但不局限为:
雌激素受体调节剂、雄激素受体调节剂、视网膜样受体调节剂、细胞毒素/细胞抑制剂、抗增殖剂、蛋白转移酶抑制剂、HMG-CoA还原酶抑制剂、HIV蛋白激酶抑制剂、逆转录酶抑制剂、血管生成抑制剂、细胞增殖及生存信号抑制剂、干扰细胞周期关卡的药物和细胞凋亡诱导剂,细胞毒类药物、酪氨酸蛋白抑制剂、EGFR抑制剂、VEGFR抑制剂、丝氨酸/苏氨酸蛋白抑制剂、Bcr-Abl抑制剂,c-Kit抑制剂,Met抑制剂,Raf抑制剂,MEK抑制剂,MMP抑制剂,拓扑异构酶抑制剂、组氨酸去乙酰化酶抑制剂、蛋白酶体抑制剂、CDK抑制剂,Bcl-2家族蛋白抑制剂,MDM2家族蛋白抑制剂、IAP家族蛋白抑制剂、STAT家族蛋白抑制剂、PI3K抑制剂、AKT抑制剂、整联蛋白阻滞剂、干扰素-α、白介素-12、COX-2抑制剂、p53、p53激活剂、VEGF抗体、EGF抗体等。
在一个实施方案中,可以与式Ⅰ-IX化合物进行药物联用的药物或活性成分包括但不局限为:阿地白介素、阿仑膦酸、干扰素、阿曲诺英、别嘌醇、别嘌醇钠、帕洛诺司琼盐酸盐、六甲蜜胺、氨基格鲁米特、氨磷汀、氨柔比星、安丫啶、阿纳托唑、多拉司琼、aranesp、arglabin、三氧化二砷、阿诺新、5-氮胞苷、硫唑嘌呤、卡介苗或tice卡介苗、贝他定、醋酸倍他米松、倍他米松磷酸钠制剂、贝沙罗汀、硫酸博来霉素、溴尿甘、bortezomib、白消安、降钙素、阿来佐单抗注射剂、卡培他滨、卡铂、康士得、cefesone、西莫白介素、柔红霉素、苯丁酸氮芥、顺铂、克拉屈滨、克拉屈滨、氯屈磷酸、环磷酰胺、阿糖胞昔、达卡巴嗪、放线菌素D、柔红霉素脂质体、地塞米松、磷酸地塞米松、戊酸雌二醇、地尼白介素2、狄波美、地洛瑞林、地拉佐生、己烯雌酚、大扶康、多西他奇、去氧氟尿苷、阿霉素、屈大麻酚、钦-166-壳聚糖复合物、eligard、拉布立酶、盐酸表柔比星、阿瑞吡坦、表阿霉素、阿法依伯汀、红细胞生成素、依铂、左旋咪唑片、雌二醇制剂、17-β-雌二醇、雌莫司汀磷酸钠、炔雌醇、氨磷汀、羟磷酸、凡毕复、依托泊甙、法倔唑、他莫昔芬制剂、非格司亭、非那司提、非雷司替、氟尿苷、氟康唑、氟达拉滨、5-氟脱氧尿嘧啶核苷一磷酸盐、5-氟尿嘧啶、氟甲睾酮、氟他胺、福麦斯坦、1-β-D-阿糖呋喃糖胞噻啶-5’-硬脂酰磷酸酯、福莫司汀、氟维司群、丙种球蛋白、吉西他滨、吉妥单抗、甲磺酸伊马替尼、卡氮芥糯米纸胶囊剂、戈舍瑞林、盐酸格拉尼西隆、组氨瑞林、和美新、氢化可的松、赤型-羟基壬基腺嘌呤、羟基脲、替坦异贝莫单抗、伊达比星、异环磷酰胺、干扰素α、干扰素-α2、干扰素α-2A、干扰素α-2B、干扰素α-nl、干扰素α-n3、干扰素β、干扰素γ-la、白细胞介素-2、内含子A、易瑞沙、依立替康、凯特瑞、硫酸香菇多糖、来曲唑、甲酰四氢叶酸、亮丙瑞林、亮丙瑞林醋酸盐、左旋四咪唑、左旋亚叶酸钙盐、左甲状腺素钠、左甲状腺素钠制剂、洛莫司汀、氯尼达明、屈大麻酚、氮芥、甲钴胺、甲羟孕酮醋酸酯、醋酸甲地孕酮、美法仑、酯化雌激素、6-琉基嘌呤、美司钠、氨甲蝶呤、氨基乙酰丙酸甲酯、米替福新、美满霉素、丝裂霉素C、米托坦、米托葱醌、曲洛司坦、柠檬酸阿霉素脂质体、奈达铂、聚乙二醇化非格司亭、奥普瑞白介素、neupogen、尼鲁米特、三苯氧胺、NSC-631570、重组人白细胞介素1-β、奥曲肽、盐酸奥丹西隆、去氢氢化可的松口服溶液剂、奥沙利铂、紫杉醇、泼尼松磷酸钠制剂、培门冬酶、派罗欣、喷司他丁、溶链菌制剂、盐酸匹鲁卡品、毗柔比星、普卡霉素、卟吩姆钠、泼尼莫司汀、司替泼尼松龙、泼尼松、倍美力、丙卡巴脐、重组人类红细胞生成素、雷替曲塞、利比、依替膦酸铼-186、美罗华、力度伸-A、罗莫肽、盐酸毛果芸香碱片剂、奥曲肽、沙莫司亭、司莫司汀、西佐喃、索布佐生、唬钠甲强龙、帕福斯酸、干细胞治疗、链佐星、氯化锶-89、左旋甲状腺素钠、他莫昔芬、坦舒洛辛、他索那明、tastolactone、泰索帝、替西硫津、替莫唑胺、替尼泊苷、丙酸睾酮、甲睾酮、硫鸟嘌呤、噻替哌、促甲状腺激素、替鲁膦酸、拓扑替康、托瑞米芬、托西莫单抗、曲妥珠单抗、曲奥舒凡、维A酸、甲氨喋呤片剂、三甲基密胺、三甲曲沙、乙酸曲普瑞林、双羟萘酸曲普瑞林、优福定、尿苷、戊柔比星、维司力农、长春碱、长春新碱、长春酰胺、长春瑞滨、维鲁利秦、右旋丙亚胺、净司他丁斯酯、枢复宁、紫杉醇蛋白质稳定制剂、acolbifene、干扰素r-lb、affinitak、氨基喋呤、阿佐昔芬、asoprisnil、阿他美坦、阿曲生坦、BAY43-9006、阿瓦斯丁、CCI-779、CDC-501、西乐葆、西妥昔单抗、克立那托、环丙孕酮醋酸酯、地西他滨、DN-101、阿霉素-MTC、dSLIM、度他雄胺、edotecarin、依氟鸟氨酸、依喜替康、芬维A胺、组胺二盐酸盐、组氨瑞林水凝胶植入物、钬-166DOTMP、伊班膦酸、干扰素γ、内含子-PEG、ixabepilone、匙孔形血蓝蛋白、L-651582、兰乐肽、拉索昔芬、libra、lonafamib、米泼昔芬、米诺屈酸酯、MS-209、脂质体MTP-PE、MX-6、那法瑞林、奈莫柔比星、新伐司他、诺拉曲特、奥利默森、onco-TCS、osidem、紫杉醇聚谷氨酸酯、帛米酸钠、PN-401、QS-21、夸西洋、R-1549、雷洛昔芬、豹蛙酶、13-顺维A酸、沙铂、西奥骨化醇、T-138067、tarceva、二十二碳六烯酸紫杉醇、胸腺素αl、嘎唑呋林、tipifarnib、替拉扎明、TLK-286、托瑞米芬、反式MID-lo7R、伐司朴达、伐普肽、vatalanib、维替泊芬、长春氟宁、Z-100和唑来麟酸或它们的组合。
下列实施例中所用试剂均可购买得到。
以下实施例对本发明做进一步的描述,但该实施例并非用于限制本发明的保护范围。
实施例中所用试剂的英文简称对应的中文名称如下:
英文简称 | 中文名称 |
DMSO | 二甲基亚砜 |
THF | 四氢呋喃 |
H<sub>2</sub>O | 水 |
EtOH | 乙醇 |
CDI | N,N’-羰基-二咪唑 |
TFA | 三氟乙酸 |
TfOH | 三氟甲基磺酸 |
DMF | N,N-二甲基甲酰胺 |
实施例1
8-(6-甲氧基吡啶-3-基)-1-(4-(哌嗪-1-基)-3-三氟甲基苯基)-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-001)
化合物1-2a的合成:在250ml反应瓶中,将化合物1-1a(2.25g,10mmol),无水哌嗪(1.29g,15mmol)和K2CO3(2.76g,20mmol)加入20ml DMSO中,氩气保护,80℃搅拌反应4h。反应结束,冷却至室温,加入100ml水,用乙酸乙酯萃取(100ml×3),合并有机层,无水硫酸钠干燥,减压旋蒸得到粗品,经柱层析纯化(二氯甲烷:甲醇=10:1),得到黄色固体2.36g,收率86%。
化合物1-3a的合成:在100ml反应瓶中,将化合物1-2a(2.75g,10mmol)溶于10mlTHF中,再加入三乙胺(1.67ml,12mmol),10min后,再加入醋酸酐(1.13ml,12mmol),室温搅拌反应2h。二氯甲烷萃取(100ml×3),水和饱和氯化钠洗涤,合并有机层,无水硫酸钠干燥,减压旋蒸得到粗品,直接用于下一步反应。
化合物1-4a的合成:在250ml反应瓶中,将化合物1-3a(3.17g,10mml),铁粉(2.78g,50mmol),氯化铵(4.28g,80mmol)溶于50ml EtOH/H2O(4:1)中,80℃回流反应过夜。反应结束,用硅藻土抽滤,加水,再用碳酸钠调pH至碱性,二氯甲烷萃取(100ml×3),合并有机层,无水硫酸钠干燥,减压旋蒸得到粗品,重结晶得浅黄色固体2.32g,收率81%。1H NMR(400MHz,DMSO-d6)δ7.08(d,J=8.4Hz,1H),6.89(d,J=2.8Hz,1H),6.77(dd,J=8.4Hz,2.8Hz,1H),3.88-3.97(m,2H),3.68(brs,2H),3.39-3.52(m,2H),2.74-2.79(m,4H),2.10(s,3H);ESI-MS:m/z 288.1[M+H]+.
化合物1-5a的合成:在250ml反应瓶中,0℃下,将化合物1-4a(2.00g,7mmol)溶于15ml HCl,再加入10ml水搅拌至溶解;接着,在0℃下,向混合液滴加5ml NaNO2(0.68g,9.8mmol)的水溶液,0℃下继续反应1h;最后,在0℃下,向混合液滴加5ml NaN3(0.64g,9.8mmol)的水溶液,继续搅拌反应0.5h。反应结束,用K2CO3水溶液中和,乙酸乙酯萃取(100ml×3),合并有机层,无水硫酸钠干燥,45℃减压旋蒸得到粗品,经柱层析纯化(二氯甲烷:甲醇=50:1(V/V)),得到浅棕色固体1.82g,收率83%。
化合物1-7a的合成:将化合物1-6a(4.70g,10mmol)、化合物1-5a(3.44g,11mmol)、CuI(0.19g,1mmol)和K2CO3(2.76g,20mmol)加入25ml反应瓶中,氩气保护,并在110℃加热下,将20ml DMSO加入搅拌反应4h。反应结束,冷却至室温,加2ml氨水淬灭,二氯甲烷萃取(50ml×3),饱和氯化钠和水洗涤,合并有机层,无水硫酸钠干燥,减压旋蒸得到粗品,经柱层析纯化(乙酸乙酯),得到白色固体3.41g,收率52%。1H NMR(400MHz,DMSO-d6)δ7.93(d,J=2.4Hz,1H),7.84(dd,J=8.4Hz,2.4Hz,1H),7.61(d,J=8.4Hz,1H),7.55(dd,J=9.2Hz,J=2.4Hz,1H),7.43(d,J=2.0Hz,1H),7.34(d,J=9.2Hz,1H),7.17(d,J=8.8Hz,2H),6.82(d,J=8.8Hz,2H),3.79-3.94(m,2H),3.75(s,3H),3.67-3.70(m,2H),3.06-3.11(m,4H),2.17(s,3H);ESI-MS:m/z 655.1[M+H]+.
化合物1-8a的合成:在25ml反应瓶中,将化合物1-7a(3.27g,5mmol)加入5ml乙醇和10ml浓盐酸中,120℃回流反应过夜。反应结束,加水,抽滤,滤饼烘箱干燥得粗品,直接用于下一步反应。
化合物1-9a的合成:在25ml反应瓶中,将化合物1-8a(3.06g,5mmol)溶于TFA(200mmol)和TfOH(25mmol)中,室温搅拌过夜。反应结束,加水淬灭,饱和碳酸氢钠调pH至碱性,抽滤,滤饼烘箱干燥得粗品,直接用于下一步反应。
化合物RI-001的合成:将化合物1-9a(0.49g,1mmol)、化合物1-10a(0.23g,1.5mmol)、(PPh3)4Pd(23mg,0.02mmol)和Cs2CO3(0.65g,2mmol)加入25ml反应瓶,氩气保护,再加入20ml DMF/H2O(3:1),80℃回流反应过夜。反应结束,加水淬灭,抽滤,滤饼经柱层析纯化(二氯甲烷:甲醇:三乙胺=100:10:1),得到白色固体0.35g,收率67%。1HNMR(400MHz,DMSO-d6)δ8.31(d,J=2.4Hz,1H),8.20(dd,J=8.4Hz,2.4Hz,1H),8.08(d,J=2.4Hz,1H),7.87-7.94(m,2H),7.56-7.64(m,2H),7.07(d,J=2.0Hz,1H),6.82(d,J=8.4Hz,1H),3.85(s,3H),3.15-3.17(m,8H);ESI-MS:m/z 522.1[M+H]+.
实施例2
1-(3-氟-4-哌嗪-1-基)-苯基)-8-(6-甲氧基吡啶-3-基)-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-002)
合成方法如实施例1,得到白色固体0.20g,收率63%。
1HNMR(400MHz,DMSO-d6)δ8.15(d,J=2.4Hz,1H),7.91(dd,J=8.4Hz,2.0Hz,1H),7.83(dd,J=8.8Hz,2.0Hz,1H),7.62-7.68(m,2H),7.57(d,J=8.4Hz,1H),7.39-7.44(m,1H),7.16(d,J=2.0Hz,1H),6.88(d,J=8.8Hz,1H),3.87(s,3H),3.20-3.22(m,4H),3.05-3.07(m,4H);ESI-MS:m/z 472.1[M+H]+.
实施例3
8-(6-甲氧基吡啶-3-基)-1-(4-(哌嗪-1-基)-苯基-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-003)
合成方法如实施例1,白色固体0.15g,收率72%。
1HNMR(400MHz,DMSO-d6)δ8.15(d,J=2.4Hz,1H),7.86(dd,J=8.4Hz,2.0Hz,1H),7.54-7.62(m,3H),7.44(d,J=8.8Hz,1H),7.20-7.25(m,3H),6.83(d,J=8.8Hz,1H),3.87(s,3H),3.32-3.46(m,4H),2.89-3.03(m,4H);ESI-MS:m/z 454.1[M+H]+.
实施例4
8-(6-甲氧基吡啶-3-基)-1-(3-甲基-4-(哌嗪-1-基)-苯基-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-004)
合成方法如实施例1,得到白色固体0.35g,收率74%。
1HNMR(400MHz,DMSO-d6)δ8.10(d,J=2.4Hz,1H),7.89(dd,J=8.4Hz,2.0Hz,1H),7.62-7.65(m,3H),7.56(d,J=8.4Hz,1H),7.34(d,J=8.4Hz,1H),7.14(d,J=2.0Hz,1H),6.84(d,J=8.8Hz,1H),3.86(s,3H),3.17(m,4H),2.98(m,4H),2.39(s,3H);ESI-MS:m/z468.1[M+H]+.
实施例5
1-(3-甲氧基-4-(哌嗪-1-基)-苯基-8-(6-甲氧基吡啶-3-基)-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-005)
合成方法如实施例1,得到白色固体0.15g,收率58%。
1HNMR(400MHz,DMSO-d6)δ8.10(s,1H),7.87(d,J=8.0Hz,1H),7.64(d,J=7.2Hz,1H),7.55(d,J=8.4Hz,1H),7.40(s,1H),7.32(d,J=8.0Hz,1H),7.20(d,J=8.4Hz,1H),7.14(s,1H),6.82(d,J=8.8Hz,1H),3.86(s,3H),3.81(s,3H),3.06(m,4H),2.92(m,4H);ESI-MS:m/z 484.1[M+H]+.
实施例6
1-(3-氯-4-(哌嗪-1-基)-苯基-8-(6-甲氧基吡啶-3-基)-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-006)
合成方法如实施例1,得到白色固体0.46g,收率57%。
1H NMR(400MHz,DMSO-d6)δ8.14(s,1H),8.10(s,1H),7.87(d,J=8.0Hz,1H),7.64(d,J=7.2Hz,1H),7.55(d,J=8.4Hz,1H),7.40(s,1H),7.32(d,J=8.0Hz,1H),7.20(d,J=8.4Hz,1H),7.14(s,1H),6.82(d,J=8.8Hz,1H),3.86(s,3H),3.81(s,3H),3.06(m,4H),2.92(m,4H);ESI-MS:m/z 484.1[M+H]+.
实施例7
8-(6-甲氧基吡啶-3-基)-1-(4-哌嗪-1-基)-2三氟甲基苯基-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-007)
合成方法如实施例1,得到白色固体0.36g,收率69%。
1HNMR(400MHz,DMSO-d6)δ8.07(d,J=2.4Hz,1H),7.88(dd,J=8.8Hz,2.0Hz,1H),7.78(d,J=8.8Hz,1H),7.48-7.60(m,4H),6.81-6.85(m,2H),3.86(s,3H),3.40-3.42(m,4H),2.90-2.92(m,4H);ESI-MS:m/z 522.1[M+H]+.
实施例8
8-(6-乙氧基吡啶-3-基)-1-(4-哌嗪-1-基)-3三氟甲基苯基-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-008)
合成方法如实施例1,得到白色固体0.35g,收率66%。
1HNMR(400MHz,DMSO-d6)δ8.27(d,J=2.4Hz,1H),8.14(dd,J=8.4Hz,2.4Hz,1H),8.02(d,J=2.4Hz,1H),7.86-7.89(m,2H),7.61(dd,J=8.8Hz,2.8Hz,1H),7.54(d,J=8.8Hz,1H),7.04(d,J=2.0Hz,1H),6.75(d,J=8.8Hz,1H),4.27(q,J=6.8Hz,2H),2.96-2.98(m,4H),2.90-2.92(m,4H),1.30(t,J=6.8Hz,3H);ESI-MS:m/z 536.1[M+H]+.
实施例9
8-(3,4-二甲氧基)-苯基-1-(4-哌嗪-1-基)-3三氟甲基苯基-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-009)
合成方法如实施例1,得到白色固体0.42g,收率78%。
1HNMR(400MHz,DMSO-d6)δ12.09(brs,1H),8.27(s,1H),8.16(d,J=8.4Hz,1H),7.91(d,J=8.0Hz,1H),7.82(d,J=8.8Hz,1H),7.57(d,J=8.4Hz,1H),7.20(s,1H),6.82-6.91(m,3H),3.76(s,3H),3.74(s,3H),2.96-2.98(m,4H),2.90-2.92(m,4H);ESI-MS:m/z551.1[M+H]+.
实施例10
8-(4-羟基)-苯基-1-(4-哌嗪-1-基)-3三氟甲基苯基-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-010)
合成方法如实施例1,得到白色固体0.36g,收率73%。
1H NMR(400MHz,DMSO-d6)δ9.64(brs,1H),8.30(d,J=2.4Hz,1H),8.14(dd,J=8.4Hz,2.4Hz,1H),7.82-7.89(m,2H),7.53(d,J=8.8Hz,1H),7.11-7.14(m,3H),6.73(d,J=8.4Hz,2H),2.93-2.99(m,8H);ESI-MS:m/z 507.1[M+H]+.
实施例11
1-(4-哌嗪-1-基)-3三氟甲基苯基-8-(吡啶-3-基)--1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-011)
合成方法如实施例1,得到白色固体0.38g,收率80%。
1HNMR(400MHz,DMSO-d6)δ8.51-8.53(m,2H),8.28(s,1H),8.15(d,J=7.2Hz,1H),7.97(d,J=8.0Hz,1H),7.86(d,J=8.4Hz,1H),7.71(d,J=7.2Hz,1H),7.59(d,J=8.4Hz,1H),7.36-7.38(m,1H),7.22(s,1H),2.90-2.96(m,8H);ESI-MS:m/z 492.1[M+H]+.
实施例12
8-(2-甲氧基嘧啶-5-基)-1-(4-哌嗪-1-基)-3三氟甲基苯基---1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-012)
合成方法如实施例1,得到白色固体0.42g,收率72%。
1HNMR(400MHz,DMSO-d6)δ8.51(s,2H),8.25(d,J=2.4Hz,1H),8.16(d,J=8.4Hz,1H),7.85-7.92(m,2H),7.54(d,J=8.8Hz,1H),7.09(d,J=2.0Hz,1H),3.91(s,3H),2.96-2.98(m,4H),2.90-2.92(m,4H);ESI-MS:m/z 523.1[M+H]+.
实施例13
8-(5-甲氧基吡啶-3-基)-1-(4-哌嗪-1-基)-3三氟甲基苯基-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-013)
合成方法如实施例1,得到白色固体0.37g,收率77%。
1H NMR(400MHz,DMSO-d6)δ8.27(d,J=2.4Hz,1H),8.24(d,J=2.8Hz,1H),8.16(dd,J=8.4Hz,2.4Hz,1H),8.12(d,J=2.0Hz,1H),8.05(s,1H),7.99(dd,J=8.8Hz,2.0Hz,1H),7.86(d,J=8.8Hz,1H),7.23-7.24(m,2H),3.84(s,3H),2.98-3.16(m,8H);ESI-MS:m/z522.1[M+H]+.
实施例14
8-(6-甲基吡啶-3-基)-1-(4-哌嗪-1-基)-3三氟甲基苯基-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-014)
合成方法如实施例1,得到白色固体0.26g,收率75%。
1H NMR(400MHz,DMSO-d6)δ8.66(s,1H),8.39(s,1H),8.15(d,J=8.0Hz,1H),7.93(d,J=8.4Hz,1H),7.86(d,J=8.4Hz,1H),7.56-7.60(m,2H),7.23(d,J=8.0Hz,1H),7.17(s,1H),2.94-3.00(m,8H),2.46(s,3H);ESI-MS:m/z 506.1[M+H]+.
实施例15
8-(4-甲氧基苯基)-1-(4-哌嗪-1-基)-3三氟甲基苯基-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-015)
合成方法如实施例1,得到白色固体0.37g,收率78%。
1H NMR(400MHz,DMSO-d6)δ12.05(brs,1H),8.34(s,1H),8.20(d,J=8.0Hz,1H),7.86-7.92(m,2H),7.56(d,J=8.8Hz,1H),7.25(d,J=8.0Hz,2H),7.14(s,1H),6.92(d,J=8.0Hz,2H),3.77(s,3H),3.05-3.13(m,8H);ESI-MS:m/z 521.1[M+H]+.
实施例16
1-(4-哌嗪-1-基)-3三氟甲基苯基-8-(噻吩-3-基)-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-016)
合成方法如实施例1,得到白色固体0.35g,收率74%。
1HNMR(400MHz,DMSO-d6)δ8.28(s,1H),8.14(d,J=2.4Hz,1H),7.90-7.92(m,2H),7.52-7.60(m,3H),7.17(s,1H),6.95(s,1H),2.96-3.01(m,8H);ESI-MS:m/z 497.1[M+H]+.
实施例17
8-(呋喃-3-基)-1-(4-哌嗪-1-基)-3三氟甲基苯基-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-017)
合成方法如实施例1,得到白色固体0.22g,收率70%。
1H NMR(400MHz,DMSO-d6)δ8.26(s,1H),8.14(d,J=8.4Hz,1H),7.81-7.89(m,3H),7.73(s,1H),7.50(d,J=8.4Hz,1H),7.08(s,1H),6.29(s,1H),2.92-3.00(m,8H);ESI-MS:m/z481.1[M+H]+.
实施例18
8-(6-甲氧基吡啶-3-基)-5-甲基-1-(4-(哌嗪-1-基)-3-(三氟甲基苯基)-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-018)
化合物18-2a的合成:采用化合物18-1a以及1-5a为原料,合成方法同化合物1-7a的合成,白色固体收率50%。
化合物18-3a的合成:合成方法同化合物1-8a的合成。
化合物RI-018的合成:合成方法同化合物RI-001的合成,白色固体,收率72%。
1HNMR(400MHz,DMSO-d6)δ8.30(d,J=2.4Hz,1H),8.18(dd,J=8.4Hz,2.4Hz,1H),8.10(d,J=2.0Hz,1H),8.03(d,J=7.6Hz,1H),7.91(d,J=8.4Hz,1H),7.80(d,J=8.8Hz,1H),7.69(dd,J=8.4Hz,2.0Hz,1H),7.19(s,1H),6.83(d,J=8.4Hz,1H),3.87(s,3H),3.76(s,3H),3.04-3.10(m,8H);ESI-MS:m/z 536.1[M+H]+.
实施例19
1-(3-氟-4-(哌嗪-1-基))苯基-8-(6-甲氧基吡啶-3-基)-5-甲基-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-019)
合成方法如实施例18,得到白色固体0.39g,收率69%。
1HNMR(400MHz,CDCl3)δ8.15(d,J=2.4Hz,1H),7.77(d,J=7.2Hz,1H),7.59(d,J=8.8Hz,1H),7.52-7.54(m,2H),7.33-7.37(m,2H),7.16-7.19(m,1H),6.76(d,J=7.6Hz,1H),3.95(s,3H),3.87(s,3H),3.21-3.24(m,4H),3.10-3.13(m,4H);ESI-MS:m/z 486.1[M+H]+.
实施例20
8-(6-甲氧基吡啶-3-基)-1-(4-吗啉基-3-(三氟甲基苯基)-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-020)
合成方法如实施例1,得到白色固体0.34g,收率73%。
1HNMR(400MHz,DMSO-d6)δ12.04(s,1H),8.30(d,J=2.8Hz,1H),8.20(dd,J=8.4Hz,2.8Hz,1H),8.08(d,J=2.8Hz,1H),7.97(d,J=8.4Hz,1H),7.90(dd,J=8.8Hz,2.0Hz,1H),7.64(dd,J=8.4Hz,2.8Hz,1H),7.57(d,J=8.8Hz,1H),7.08(s,1H),6.82(d,J=8.4Hz,1H),3.84(s,3H),3.81(t,J=4.4Hz,4H),3.07(t,J=4.4Hz,4H);ESI-MS:m/z523.1[M+H]+.
实施例21
8-(6-甲氧基吡啶-3-基)-1-(4-(4-甲基哌嗪-1-基)-3-三氟甲基苯基)-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-021)
合成方法如实施例1,得到白色固体0.31g,收率73%。
1HNMR(400MHz,DMSO-d6)δ12.06(s,1H),8.30(s,1H),8.18(d,J=7.6Hz,1H),8.07(s,1H),7.94(d,J=8.4Hz,1H),7.89(d,J=8.0Hz,1H),7.62(d,J=7.6Hz,1H),7.56(d,J=8.4Hz,1H),7.06(s,1H),6.80(d,J=8.4Hz,1H),3.84(s,3H),3.12(m,4H),2.73(m,4H),2.42(s,3H);ESI-MS:m/z 536.1[M+H]+.
实施例22
1-(4-(4-乙酰基哌嗪-1-基)-3-三氟甲基苯基)-8-(6-甲氧基吡啶-3-基)-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-022)
合成方法如实施例1,得到白色固体0.23g,收率72%。
1HNMR(400MHz,DMSO-d6)δ12.02(s,1H),8.31(s,1H),8.18(d,J=7.6Hz,1H),8.06(s,1H),7.95(d,J=7.2Hz,1H),7.88(d,J=6.8Hz,1H),7.54-7.62(m,2H),7.06(s,1H),6.82(d,J=7.6Hz,1H),3.85(s,3H),3.60-3.64(m,4H),3.02-3.06(m,4H),2.08(s,3H);ESI-MS:m/z 564.1[M+H]+.
实施例23
8-(6-甲氧基吡啶-3-基)-1-(4-(4-(2-吗啉乙基)-哌嗪-1-基)-3-三氟甲基苯基)-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-023)
化合物RI-023的合成:
在100ml反应瓶中,将化合物1-8a(3.06g,5mmol)、N-(2-氯乙基)吗啉(1.12g,7.5mmol)和碳酸钾(1.04g,7.5mmol)加入DMSO(20ml)中,60℃加热反应过夜。反应结束,加水淬灭,抽滤,滤饼烘箱干燥得粗品化合物23-1a,直接用于下一步反应。
在25ml反应瓶中,将化合物23-1a(1.45g,2mmol)溶于TFA(80mmol)和TfOH(10mmol)中,室温搅拌过夜。反应结束,加水淬灭,饱和碳酸氢钠调pH至碱性,抽滤,滤饼烘箱干燥得粗品化合物23-2a,直接用于下一步反应。
将化合物23-2a(0.6g,1mmol)、(6-甲氧基吡啶-3-基)硼酸(0.23g,1.5mmol)、(PPh3)4Pd(23mg,0.02mmol)和Cs2CO3(0.65g,2mmol)加入25ml反应瓶,氩气保护,再加入20ml DMF/H2O(3:1),80℃回流反应过夜。反应结束,加水淬灭,抽滤,滤饼经柱层析纯化(二氯甲烷:甲醇:三乙胺=100:10:1),得到化合物RI-023,白色固体0.35g,收率56%。1H NMR(400MHz,DMSO-d6)δ12.01(s,1H),8.30(d,J=2.0Hz,1H),8.18(dd,J=8.4Hz,2.0Hz,1H),8.03(d,J=2.4Hz,1H),7.96(d,J=8.4Hz,1H),7.86(dd,J=8.8Hz,1.6Hz,1H),7.61(dd,J=8.8Hz,2.4Hz,1H),7.53(d,J=8.8Hz,1H),7.03(s,1H),6.80(d,J=8.4Hz,1H),4.16(t,J=6.0Hz,2H),3.84(s,3H),3.56(t,J=4.4Hz,4H),3.33-3.35(m,4H),3.00-3.03(m,4H),2.57(t,J=6.0Hz,2H),2.42-2.44(m,4H);ESI-MS:m/z 635.1[M+H]+.
实施例24
5-(2-羟基乙基)-1-(4-(4-(2-羟基乙基)-哌嗪-1-基)-3-三氟甲基苯基)-8-(6-甲氧基吡啶-3-基)-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-024)
合成方法如实施例23,得到白色固体0.35g,收率61%。
1HNMR(400MHz,DMSO-d6)δ8.31(s,1H),8.19(d,J=7.6Hz,1H),8.09(s,1H),7.90-8.00(m,3H),7.68(d,J=7.6Hz,1H),7.16(s,1H),6.85(d,J=8.4Hz,1H),5.00(t,J=5.6Hz,1H),4.84(t,J=5.6Hz,1H),3.84(s,3H),3.56(t,J=4.4Hz,4H),3.33-3.35(m,4H),3.00-3.03(m,4H),2.57(t,J=6.0Hz,2H),2.42-2.44(m,4H);ESI-MS:m/z 635.1[M+H]+.
实施例25
1-(4-(4-乙酰基哌嗪-1-基)-3-甲基苯基)-5-(4-甲氧基苄基)-8-(6-甲氧基吡啶-3-基)-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-025)
合成方法如实施例1,得到白色固体0.35g,收率74%。
1HNMR(400MHz,CDCl3)δ8.01(d,J=2.4Hz,1H),7.59(dd,J=8.4Hz,2.4Hz,1H)),7.44-7.50(m,5H),7.20-7.24(m,3H),6.83(d,J=6.8Hz,2H),6.69(d,J=8.4Hz,1H),3.91(s,3H),3.82-3.84(m,2H),3.74(s,3H),3.69-3.71(m,2H),3.01-3.06(m,4H),2.45(s,3H),2.18(s,3H);ESI-MS:m/z 630.1[M+H]+.
实施例26
5-(4-甲氧基苄基)-8-(6-甲氧基吡啶-3-基)-1-(3-甲基-4-(哌嗪-1-基)-苯基)-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-026)
合成方法如实施例1,得到白色固体0.2g,收率61%。
1HNMR(400MHz,DMSO-d6)δ8.09(s,1H),7.88(d,J=8.4Hz,1H),7.57-7.7(m,4H),7.44(d,J=8.0Hz,1H),7.21-7.25(m,3H),6.88-6.90(m,3H),3.86(s,3H),3.70(s,3H),3.25-3.40(m,8H),2.41(s,3H);ESI-MS:m/z 588.1[M+H]+.
实施例27
1-(4-(4-乙酰基哌嗪-1-基)-3-甲氧苯基)-5-(4-甲氧基苄基)-8-(6-甲氧基吡啶-3-基)-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-027)
合成方法如实施例1,得到白色固体0.30g,收率58%。
1H NMR(400MHz,CDCl3)δ8.02(d,J=2.0Hz,1H),7.47(dd,J=8.4Hz,2.0Hz,1H),7.57-7.7(m,4H),7.44(d,J=8.0Hz,1H),7.21-7.25(m,3H),3.91(s,3H),3.90(s,3H),3.83-3.85(m,2H),3.74(s,3H),3.69-3.72(m,2H),3.15-3.20(m,4H),2.16(s,3H);ESI-MS:m/z 646.1[M+H]+.
实施例28
1-(3-甲氧基-4-(哌嗪-1-基)-苯基)-5-(4-甲氧基苄基)-8-(6-甲氧基吡啶-3-基)-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-028)
合成方法如实施例1,得到白色固体0.18g,收率61%。
1HNMR(400MHz,DMSO-d6)δ8.08(d,J=2.4Hz,1H),7.88(dd,J=8.4Hz,2.0Hz,1H),7.63(d,J=8.8Hz,2H),7.45(d,J=2.4Hz,1H),7.23(d,J=8.4Hz,1H),7.21-7.25(m,3H),3.85(s,3H),3.83(s,3H),3.81(s,3H),3.05-3.12(m,4H),2.93-2.97(m,4H);ESI-MS:m/z604.1[M+H]+.
实施例29
8-(6-甲氧基吡啶-3-基)-1-(4-(哌嗪-1-基)-3-三氟甲基苯基)-1,5-二氢-4H-吡唑[4,3-c]喹啉-4-酮(RI-029)
化合物29-7a的合成:
在100ml反应瓶中,将化合物29-1a(5g,20.32mmol)和CDI(3.62g,22.36mmol)加入40ml THF中,室温搅拌反应1h;再将混合均匀的EtO2CCH2CO2K(5.19g,30.48mmol)和氯化镁(1.93g,20.32mmol)加入上述混合液中,回流反应过夜。反应结束,冷却至室温,分别用10%硫酸氢钾和饱和氯化钠溶液洗涤,乙酸乙酯萃取(100ml×3),合并有机层,无水硫酸钠干燥,减压旋蒸得到化合物29-2a粗品,直接用于下一步反应。
在100ml反应瓶中,将化合物29-2a(1.6g,5.06mmol)和化合物29-3a(3.36ml,25.31mmol)加入20ml甲苯中,回流反应4h。反应结束,冷却至室温,除去溶剂得到化合物29-4a粗品,直接用于下一步反应。
在100ml反应瓶中,将化合物29-4a(1.88g,5.06mmol)和化合物29-5a(1.25g,5.06mmol)加入20ml无水乙醇中,回流反应过夜。反应结束,冷却至析出固体,抽滤得到化合物29-6a粗品,直接用于下一步反应。
在100ml反应瓶中,将化合物29-6a(1g,1.93mmol),铁粉(0.54g,9.65mmol),氯化铵(0.83g,15.44mmol)溶于20ml EtOH/H2O(4:1)中,80℃回流过夜反应。反应结束,用硅藻土抽滤,加水,再用碳酸钠调pH至碱性,二氯甲烷萃取(100ml×3),合并有机层,无水硫酸钠干燥,减压旋蒸得到粗品,重结晶得化合物29-7a,浅黄色固体0.7g,收率74%。1H NMR(400MHz,DMSO-d6)δ8.26(s,1H),7.86(d,J=2.4Hz,1H),7.80(d,J=8.8Hz,1H),7.65(dd,J=8.4Hz,2.4Hz,1H),7.25(dd,J=8.8Hz,2.4Hz,1H),7.18(d,J=2.4Hz,1H),6.60(d,J=8.8Hz,1H),5.24(s,2H),4.12(q,J=7.2Hz,2H),1.13(t,J=7.2Hz,3H);ESI-MS:m/z488.0[M+H]+.
化合物RI-029的合成:
在50ml反应瓶中,将化合物29-7a(0.5g,1.01mmol)溶于10ml EtOH中,在70℃下,滴加10d浓盐酸,反应过夜。反应结束,冷却至至室温,抽滤得到粗品化合物29-8a,直接用于下一步反应。
将化合物29-8a(0.44g,1mmol)、(6-甲氧基吡啶-3-基)硼酸(0.23g,1.5mmol)、(PPh3)Cl2Pd(70mg,0.1mmol)和Cs2CO3(0.65g,2mmol)加入25ml反应瓶,氩气保护,再加入12ml DMF/H2O(3:1),80℃回流反应过夜。反应结束,加水淬灭,抽滤得到粗品化合物29-9a,直接用于下一步反应。
将化合物29-9a(0.47g,1mmol)、哌嗪(0.34g,4mmol)和Cs2CO3(0.65g,2mmol)加入25ml反应瓶,再加入10ml DMF,140℃回流反应过夜。反应结束,加水淬灭,抽滤,滤饼经柱层析纯化(二氯甲烷:甲醇:三乙胺=100:10:1(V/V)),得到化合物RI-029,白色固体0.2g,收率38%。1HNMR(400MHz,DMSO-d6)δ11.71(s,1H),8.43(s,1H),8.09-8.14(m,3H),7.83-7.90(m,2H),7.64(d,J=8.4Hz,1H),7.55(d,J=8.4Hz,1H),7.05(s,1H),6.84(d,J=8.4Hz,1H),3.85(s,3H),3.17-3.27(m,8H);ESI-MS:m/z 521.1[M+H]+.
实施例30
8-(6-甲氧基吡啶-3-基)-1-(萘-1-基)-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-030)
合成方法如实施例1。
1HNMR(400MHz,DMSO-d6)δ12.08(s,1H),8.56(s,1H),8.36(d,J=8.8Hz,1H),8.20(t,J=7.4Hz,2H),8.02(d,J=2.0Hz,1H),7.95(dd,J=8.6Hz,1.7Hz,1H),7.85(dd,J=8.6Hz,1.4Hz,1H),7.77(dd,J=12.2Hz,6.4Hz,2H),7.59(d,J=8.6Hz,1H),7.51(dd,J=8.6Hz,2.4Hz,1H),7.34(s,1H),6.67(d,J=8.6Hz,1H),3.78(s,3H);ESI-MS:m/z 420.1[M+H]+.
实施例31
7-(6-甲氧基吡啶-3-)-1-(4-(哌嗪-1-基)-3-三氟甲基苯基)-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-031)
合成方法如实施例1,得到白色固体0.14g,收率62%。
1H NMR(400MHz,DMSO-d6)δ8.28(d,J=1.6Hz,1H),8.16(d,J=8.4Hz,1H),8.07(d,J=1.8Hz,1H),7.89(d,J=8.4Hz,2H),7.64(dd,J=8.6Hz,2.2Hz,1H),7.57(d,J=8.6Hz,1H),7.07(d,J=1.2Hz,1H),6.81(d,J=8.6Hz,1H),3.84(s,3H),3.02-3.04(m,8H);ESI-MS:m/z522.1[M+H]+.
实施例32
8-(6-甲氧基吡啶-3-基)-1-(4-(哌嗪-1-基)-3-三氟甲基苯基)-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮甲磺酸盐(RI-032)
化合物RI-032的合成:
在25ml反应瓶中,将化合物RI-001(200mg)加入3ml甲醇中,再将溶于2ml甲醇的甲磺酸(0.1ml)缓慢滴加至反应瓶中;70℃回流2h,减压除去溶剂,加入2ml乙醇,抽滤,滤饼真空干燥,得到化合物RI-032,白色固体150mg,产率64%。1HNMR(400MHz,DMSO-d6)δ12.06(s,1H),8.84(s,2H),8.35(s,1H),8.24(d,J=7.6Hz,1H),8.13(s,1H),7.97(d,J=8.4Hz,1H),7.92(d,J=8.8Hz,1H),7.67-7.61(m,1H),7.59(d,J=8.8Hz,1H),7.12(s,1H),6.86(d,J=8.6Hz,1H),3.86(s,3H),3.20-3.37(m,8H),2.36(s,3H);ESI-MS:m/z 522.1[M+H]+.
实施例33
8-(6-甲氧基吡啶-3-基)-1-(3-三氟甲基苯基)-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-033)
合成方法如实施例1,得到白色固体0.62g,收率78%。
1H NMR(400MHz,DMSO-d6)δ12.07(s,1H),8.43(s,1H),8.19-8.25(m,2H),8.12(d,J=2.2Hz,1H),8.05(t,J=7.9Hz,1H),7.87(dd,J=8.6Hz,1.6Hz,1H),7.63(dd,J=8.6Hz,2.4Hz,1H),7.58(d,J=8.6Hz,1H),7.25(d,J=1.2Hz,1H),6.82(d,J=8.6Hz,1H),3.85(s,3H);ESI-MS:m/z 437.1[M+H]+.
实施例34
1-(4-(4-(2-二甲基氨基乙基)哌嗪-1-基)-3-三氟甲基苯基)-8-(6-甲氧基吡啶-3-基)-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-034)
合成方法如实施例23,得到白色固体0.16g,收率51%。
1H NMR(400MHz,DMSO-d6)δ12.06(s,1H),8.32(d,J=2.4Hz,1H),8.20(dd,J=8.4Hz,2.4Hz,1H),8.09(d,J=2.0Hz,1H),7.96(d,J=8.6Hz,1H),7.91(dd,J=8.8Hz,2.0Hz,1H),7.65(dd,J=8.6Hz,2.6Hz,1H),7.59(d,J=8.8Hz,1H),7.09(d,J=1.8Hz,1H),6.84(d,J=8.6Hz,1H),4.28(t,J=5.2Hz,2H),3.87(s,3H),3.56-3.68(m,4H),3.08-3.10(m,2H),3.05-3.07(m,4H),2.61(s,6H);ESI-MS:m/z 592.1[M+H]+.
实施例35
1-(4-(4-(2-(4-(4-甲氧基丁氧基)乙氧基)哌嗪-1-基)-3-三氟甲基苯基)-8-(6-甲氧基吡啶-3-基)-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮(RI-035)
合成方法如实施例23,得到白色固体0.45g,收率67%。
1H NMR(400MHz,DMSO-d6)δ12.04(s,1H),8.27(d,J=2.2Hz,1H),8.15(dd,J=8.8Hz,2.0Hz,1H),8.08(d,J=2.4Hz,1H),7.88-7.93(m,2H),7.64(dd,J=8.6Hz,2.6Hz,1H),7.57(d,J=8.6Hz,1H),7.07(d,J=1.6Hz,1H),6.81(d,J=8.6Hz,1H),3.85(s,3H),3.52-3.59(m,8H),3.48-3.41(m,2H),3.24(s,3H),3.06-3.07(m,4H),2.65-2.70(m,4H),2.58(t,J=5.8Hz,2H);ESI-MS:m/z 667.1[M+H]+.
实施例36
2-(4-(4-(8-(6-甲氧基吡啶-3-基)-4-氧代-4,5-二氢-1H-[1,2,3]三氮唑[4,5-c]喹啉-1-基)-2-三氟甲基苯基)哌嗪-1-基)乙基磷酸二氢(RI-036)
化合物RI-036的合成:
化合物36-1a的合成:合成方法同化合物RI-023的合成。
在10ml反应瓶中,将化合物36-1a(100mg,0.18mmol)溶于DMF(1ml),再将溶于2ml乙腈的1H-四氮唑(7mg,0.11mmol)加入,室温搅拌反应30min;然后,将N,N-二异丙基亚磷酰胺二叔丁酯(0.11ml,0.36mmol)加入上述混合液中,继续反应3h,再转0℃,向混合液中加入0.05ml 5mol/L的叔丁基过氧化氢,转室温反应1h。反应结束,加水淬灭,乙酸乙酯萃取(10ml×3),合并有机层,无水硫酸钠干燥,减压旋蒸得到粗品,将该粗品加入1ml 1M HCl,室温搅拌反应2h。反应结束,除去溶剂,固体真空干燥,1ml(二氯甲烷:甲醇=10:1)洗涤,得到化合物RI-036,白色固体20mg,收率17%。1HNMR(400MHz,DMSO-d6)δ12.08(s,1H),8.36(d,J=1.8Hz,1H),8.24(d,J=7.8Hz,1H),8.11(d,J=2.0Hz,1H),7.91-7.98(m,2H),7.70-7.51(m,2H),7.13(s,1H),6.85(d,J=8.6Hz,1H),4.22(t,J=19.6Hz,2H),3.86(s,3H),3.39-3.50(m,4H),3.30-3.38(m,4H),2.54-2.55(m,2H);ESI-MS:m/z 645.1[M+H]+.
实施例37
8-(6-甲氧基吡啶-3-基)-1-(4-(哌嗪-1-基)-3-三氟甲基苯基)-1,5-二氢-4H-咪唑并[4,5-c]喹啉-4-酮(RI-037)
化合物37-4a的合成:
将化合物37-1a(5g,18.59mmol),加入100ml反应瓶中,再加入20ml三氯氧磷,110℃下回流反应4h。反应结束,冷却至0℃,冰水淬灭,用饱和碳酸氢钠调pH至碱性,再用乙酸乙酯萃取(100ml×3),合并有机层,无水硫酸钠干燥,减压旋蒸得到化合物37-2a粗品,直接用于下一步反应。
在100ml反应瓶中,将化合物37-3a(3.45g,12mmol)溶于30ml冰乙酸中,再缓慢加入化合物37-2a(2.88g,10mmol),室温搅拌反应3h。反应结束,加水淬灭,二氯甲烷萃取(100ml×3),饱和氯化钠洗涤,合并有机层,无水硫酸钠干燥,减压旋蒸得到粗品,经柱层析纯化(二氯甲烷),得到化合物37-4a,黄色固体4.04g,收率75%。1H NMR(400MHz,DMSO-d6)δ10.49(s,1H),9.47(s,1H),7.91(d,J=8.8Hz,1H),7.78(dd,J=8.8Hz,2.0Hz,1H),7.60(d,J=2.0Hz,1H),7.47(d,J=2.4Hz,1H),7.34(d,J=8.6Hz,1H),7.28(d,J=2.8Hz,1H),3.80-3.75(m,2H),3.64-3.58(m,2H),2.97-2.89(m,4H),2.14(s,3H);ESI-MS:m/z 538.1[M+H]+.
化合物37-5a的合成:
在250ml反应瓶中,将化合物37-4a(2.50g,4.64mml),铁粉(1.29g,23.19mmol),氯化铵(1.98g,37.12mmol)溶于50ml EtOH/H2O(4:1)中,80℃回流过夜反应。反应结束,用硅藻土抽滤,加水,再用碳酸钠调pH至碱性,二氯甲烷萃取(100ml×3),合并有机层,无水硫酸钠干燥,减压旋蒸得到粗品,重结晶得化合物37-5a,浅黄色固体2.15g,收率91%。1H NMR(400MHz,DMSO-d6)δ8.60(s,1H),7.90(d,J=2.4Hz,1H),7.85(d,J=8.8Hz,1H),7.51(dd,J=9.0Hz,2.2Hz,1H),7.13(d,J=8.6Hz,1H),6.98(d,J=2.8Hz,1H),6.64(dd,J=8.6Hz,2.8Hz,1H),6.27(s,1H),4.16(s,2H),3.91-3.57(m,2H),3.48-3.54(m,2H),2.82(t,J=4.8Hz,2H),2.76(t,J=4.8Hz,2H),2.11(s,3H);ESI-MS:m/z 508.1[M+H]+.
化合物37-6a的合成:
在50ml反应瓶中,将化合物37-5a(0.6g,1.18mmol)加入12ml原甲酸三乙酯中,150℃下回流反应3h。反应结束,减压旋蒸得到粗品,经柱层析纯化(二氯甲烷:甲醇=10:1),得到化合物37-6a,白色固体0.5g,收率82%。1H NMR(400MHz,DMSO-d6)δ9.39(s,1H),8.28-8.03(m,2H),7.87(s,1H),7.69-7.76(m,2H),7.59-7.61(m,1H),7.46-7.47(m,1H),3.870-3.80(m,4H),3.01-3.19(m,4H),2.17(s,3H);ESI-MS:m/z 518.1[M+H]+.
化合物37-7a的合成:
在25ml反应瓶中,将化合物37-6a(0.52g,1.0mmol)加入0.22ml 30%过氧化氢和3ml冰乙酸中,80℃搅拌反应过夜。冷却至室温,减压旋蒸浓缩,饱和碳酸氢钠中和,抽滤,滤饼干燥得到中间体。再将上述得到的中间体加入2.5ml乙酸酐中,回流反应1h,减压旋蒸得到粗品,经柱层析纯化(二氯甲烷:甲醇=10:1),得到化合物37-7a,白色固体0.32g,收率60%。1H NMR(400MHz,DMSO-d6)δ11.83(s,1H),8.37(s,1H),8.14(d,J=2.4Hz,1H),8.08-8.01(m,1H),7.88(d,J=8.4Hz,1H),7.55(dd,J=8.8Hz,2.0Hz,1H),7.39(d,J=8.8Hz,1H),6.81(d,J=1.6Hz,1H),3.56-3.72(m,4H),3.05-2.90(m,4H),2.07(s,3H);ESI-MS:m/z534.1[M+H]+.
化合物RI-037的合成:
在25ml反应瓶中,将化合物37-7a(0.27g,0.5mmol)加入5ml乙醇和5ml浓盐酸中,120℃回流反应过夜。反应结束,加水,抽滤,滤饼烘箱干燥得化合物37-8a粗品,直接用于下一步反应。
将化合物化合物37-8a(0.49g,1mmol)、(6-甲氧基吡啶-3-基)硼酸(0.23g,1.5mmol)、(PPh3)2Cl2Pd(70mg,0.1mmol)和Cs2CO3(0.65g,2mmol)加入25ml反应瓶,氩气保护,再加入20ml DMF/H2O(3:1),80℃回流反应过夜。反应结束,加水淬灭,抽滤,滤饼经柱层析纯化(二氯甲烷:甲醇:三乙胺=100:10:1),得到化合物RI-037,白色固体0.36g,收率70%。1H NMR(400MHz,DMSO-d6)δ11.77(s,1H),8.38(s,1H),8.16(d,J=2.4Hz,1H),8.06(dd,J=8.4Hz,2.4Hz,1H),7.99(d,J=2.4Hz,1H),7.86(d,J=8.4Hz,1H),7.73(dd,J=8.6Hz,2.0Hz,1H),7.61(dd,J=8.6Hz,2.6Hz,1H),7.53(d,J=8.6Hz,1H),6.85(d,J=1.6Hz,1H),6.78(d,J=8.6Hz,1H),3.84(s,3H),2.95-3.15(m,8H);ESI-MS:m/z 521.1[M+H]+.
实施例38
8-(6-甲氧基吡啶-3-基)-1-(4-(4-(2-吗啉乙基)-哌嗪-1-基)-3-三氟甲基苯基)-1,5-二氢-4H-[1,2,3]三氮唑[4,5-c]喹啉-4-酮甲磺酸盐(RI-038)
合成方法如实施例32,得到白色固体0.16g,收率42%。
1H NMR(400MHz,DMSO-d6)δ12.05(s,1H),9.87(s,1H),8.32(d,J=2.0Hz,1H),8.20(d,J=8.4Hz,1H),8.09(d,J=2.4Hz,1H),7.96(d,J=8.4Hz,1H),7.91(dd,J=8.8Hz,1.6Hz,1H),7.64(dd,J=8.8Hz,2.4Hz,1H),7.58(d,J=8.8Hz,1H),7.09(s,1H),6.84(d,J=8.4Hz,1H),4.41-4.45(m,2H),4.00-4.03(m,2H),3.86(s,3H),3.70-3.76(m,2H),3.60-3.65(m,4H),3.43-3.46(m,4H),3.20-3.22(m,2H),3.05-3.10(m,4H),2.36(s,3H);ESI-MS:m/z 635.1[M+H]+.
实施例39
化合物的体外抗肿瘤活性:本实验使用的细胞MOLT-4(急性淋巴母细胞白血病细胞系)、KG1(急性髓性白血病细胞系)、HL60(人原髓细胞白血病细胞)、VCaP(前列腺癌)和LNCaP(前列腺癌)等细胞系,均来自ATCC或者中国科学院典型培养物保藏委员会细胞库。3000-10000个/孔的上述细胞接种到96孔板中,过夜后,加入不同浓度的化合物(0-30μM)连续处理72小时。然后加入CCK8试剂,继续孵育1-3小时,接着用超级酶标仪测定其在450nm及650nm的吸光值。使用GrapPadprism 5.0软件计算其半数抑制浓度(IC50)。
结果发现,本发明的RIOK2活性抑制分子含氮并杂环类化合物可明显抑制MOLT-4,HL-60和VCaP等肿瘤细胞的增殖。具体数据见表1-表4。
表1化合物体外抗肿瘤细胞的活性(IC50/μM)
RI-001 | RI-002 | RI-003 | RI-004 | RI-005 | RI-006 | RI-007 | RI-008 | RI-009 | RI-010 | |
MOLT-4 | 0.42±0.07 | >10 | 0.36±0.02 | 0.67±0.07 | 1.52 | |||||
HL-60 | 1.37±0.07 | >10 | 1.85±0.93 | 2.32±0.14 | 3.641 | |||||
KG-1 | 2.22±0.64 | >10 | 8.48±0.22 | >30 | 10.5 | |||||
LnCaP | 1.24±0.06 | >30 | 1.32±0.15 | 1.98±0.11 | 1.894 | |||||
vCaP | 1.40±0.24 | >30 | 3.51±0.78 | 2.65±0.11 | 0.952 | |||||
U87MG | 0.56 | 1.26 | 0.93 | 1.36 | 1.81 | 1.23 | 4.64 | 0.84 | 3.00 | 5.04 |
MNNG/HOS | 1.09 | / | 1.30 | >30 | / | |||||
HCC-1833 | 0.49 | / | 1.28 | 3.16 | / | |||||
MDA-MB-231 | 1.67±0.18 | / | 4.10±0.95 | >30 | / | |||||
MKN-1 | 0.61±0.18 | 0.90 | 0.93 | 0.95±0.16 | 5.76±2.30 | 1.31 | 4.93 | 0.68 | 2.25 | 7.00 |
K562 | 0.50 | / | 0.49 | / | / | |||||
A549 | 2.16 | / | 1.69 | / | / | |||||
U937 | 1.64 | / | 0.56 | / | / | |||||
A431 | 3.10 | / | 2.39 | / | / | |||||
NB4 | 1.92 | / | 0.89 | / | / | |||||
MV4-11 | 0.58 | / | 0.34 | / | / | |||||
MDA-MB-453 | 1.10 | / | 0.61 | / | / | |||||
EOL-1 | 2.35 | / | 1.97 | / | / | |||||
SNU-1 | 0.45 | / | 0.18 | 0.49 | / | |||||
HGC-27 | 0.45 | / | 0.32 | 0.83 | / | |||||
U251 | 1.5 | / | 1.55 | 3.04 | / |
表2化合物体外抗肿瘤细胞的活性(IC50/μM)
RI-011 | RI-012 | RI-013 | RI-014 | RI-015 | RI-016 | RI-017 | RI-018 | RI-019 | RI-020 | |
MOLT-4 | 1.183 | |||||||||
HL-60 | >30 | |||||||||
KG-1 | 3.12 | |||||||||
LnCaP | 0.945 | |||||||||
vCaP | >30 | |||||||||
U87MG | 9.61 | 4.71 | 3.97 | 4.90 | 0.55 | 1.64 | 1.88 | 0.54 | 2.78 | 3.49 |
MKN-1 | 7.31 | 6.19 | 8.50 | 3.85 | 0.75 | 1.54 | 1.32 | 0.72 | 1.44 | 6.39 |
表3化合物体外抗肿瘤细胞的活性(IC50/μM)
表4化合物体外抗肿瘤细胞的活性(IC50/μM)
RI-031 | RI-032 | RI-033 | RI-034 | RI-035 | RI-036 | RI-037 | RI-038 | |
U87MG | 2.80 | 2.81 | 10.78 | 3.11 | 5.88 | 10.55 | >30 | 1.46 |
MKN-1 | 4.01 | 1.62 | 19.22 | 5.11 | >30 | 16.77 | >30 | 1.53 |
实施例40
含氮并杂环类化合物对RIOK2激酶的亲和力Kd测试
KINOMEscanTM技术是业内最全面的检测化合物针对大量人类激酶作用的高通量筛选系统。(Fabian et al.(2005)Nat.Biotechnol.23,329;Karamanet al.(2008)Nat.Biotechnol.26,127)。KINOMEscanTM是基于竞争性结合作用而建立的检测方法,通过化合物与固定化的配体竞争性结合激酶活性位点来定量检测化合物与酶的结合能力。该测试主要包括三个组分:连接有DNA标签的激酶,固定化的配体以及被测化合物。化合物与固定化的配体的竞争能力是通过对激酶上连接的DNA标签进行定量PCR测得的。
激酶活性测试:对大多数实验,在24孔板中,带有激酶标签的T7噬菌体是在BL21来源的大肠杆菌中平行扩增。当大肠杆菌生长到对数生长期时,用冰冻保存的T7噬菌体进行感染(感染复数=0.4),并在32℃下震荡培养直到细菌溶解(90-150分钟)。将溶解物离心(6000x g)并过滤(0.2μm)除去碎片。收集的上清感染HEK293细胞并在其中扩增,由此产生可用于qPCR检测的带DNA标签的激酶。连接了生物素的小分子配体与链霉亲和素包被的磁珠在室温下反应30分钟,为实验提供亲合性的树脂。将配体化的磁珠用过量的生物素封闭,并用封闭缓冲液(SeaBlock(Pierce),1%BSA,0.05%Tween 20,1mM DTT)洗涤以除去未结合的配体,并减少非特异性的噬菌体结合。结合反应是将激酶、结合配体的磁珠,含待测试化合物的1x结合缓冲液(20%SeaBlock,0.17×PBS,0.05%Tween 20,6mM DTT)混合。待测化合物使用100%DMSO配制成100X的储备液,实验时直接稀释到反应体系中。所有的反应都在聚丙烯384孔板中进行,反应终体积为0.02ml。将测试板室温下震荡孵化1小时,将磁珠用冲洗缓冲液(1×PBS,0.05%Tween 20)洗涤磁珠。将磁珠重悬于洗脱液(1×PBS,0.05%Tween 20,0.5μM非生物素化的亲和配体),在室温下震荡孵化30分钟。通过用qPCR方法检测激酶上的DNA标签量来检测激酶的浓度。
结合常数(Kds)采用希尔方程,通过标准的剂量-响应曲线计算得到:
希尔斜率值取-1。
表5中所列为代表性化合物编号以及对应Kd结果。结果发现,本发明的RIOK2活性抑制分子含氮并杂环类化合物与RIOK2激酶的结合能力强。
表5化合物与RIOK2激酶的结合能力
以上所述实施例的各技术特征可以进行任意的组合,为使描述简洁,未对以下实施例中的各个技术特征所有可能的组合都进行描述,然而,只要这些技术特征的组合不存在矛盾,都应当认为是本说明书记载的范围。
以上所述实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对本发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。因此,本发明专利的保护范围应以所附权利要求为准。
Claims (25)
1.具有式(Ⅰ)所示结构的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子:
其中,
A1、A2、B1、B2、D和E分别独立地选自:N、CR2;
X任选自:O、S、NR3;
Ar1和Ar2分别独立地选自:取代或未取代的C6~C10芳基、取代或未取代的5~10元杂芳基;
R1任选自:H、C1~C6烷基、C3~C6环烷基、3~6元杂环烷基、C1~C8酰基、磺酰基、C6~C18芳基、C6~C18芳基取代的C1~C6烷基、5~18元杂芳基;当R1不为氢时,所述R1独立任选地被1个或多个R4取代;
各R2分别独立地选自:H、卤素、C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、C1~C18烷胺基、氨基、羟基、氰基、硝基、酯基、酰胺基、磺酰基、磺酰氨基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基、5~18元杂芳基;当R2选自C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、C1~C18烷胺基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基或5~18元杂芳基时,所述R2独立任选地被1个或多个R4取代;
R3任选自:H、C1~C18烷基、C6~C18芳基取代的C1~C18烷基、C3~C18环烷基、C6~C18芳基取代的C3~C18环烷基、C1~C8酰基、磺酰基;当R3不为氢时,所述R1独立任选地被1个或多个R4取代;
各R4分别独立地选自:H、羟基、氨基、氰基、硝基、卤素、C1~C6烷氧基、C1~C6烷基。
2.根据权利要求1所述的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子,其特征在于,Ar1和Ar2分别独立地任选自:苯基、噻唑基、呋喃基、吡咯基、吡唑基、咪唑基、吡啶基、嘧啶基、吲哚基、苯并噻唑基、苯并咪唑基、苯并呋喃基;所述Ar1和Ar2分别独立任选地被一个或多个取代基取代,或者未被取代基取代。
3.根据权利要求1所述的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子,其特征在于,其具有式(Ⅱ)或者式(III)所示结构:
其中,X1、X2、X3、X4、X5分别独立地选自:N、CR5;
X6、X7、X8、X9和X10分别独立地选自:N、CR6、CR;并且X6、X7、X8、X9和X10中至少有一个选自CR;
Y选自:O、S、NR3;
各R5分别独立地选自:H、卤素、C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、C1~C18烷胺基、氨基、羟基、氰基、硝基、酯基、酰胺基、磺酰基、磺酰氨基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基、5~18元杂芳基;当R5选自C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、C1~C18烷胺基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基或5~18元杂芳基时,所述R5独立任选地被1个或多个R4取代;
各R6分别独立地任选自:H、卤素、C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、烷基C1~C18烷胺基、氨基、羟基、氰基、硝基、酯基、酰胺基、磺酰基、磺酰氨基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基、5~18元杂芳基;当R6选自C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、C1~C18烷胺基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基或5~18元杂芳基时,所述R6独立任选地被1个或多个R4取代;
各R7,R8分别独立地任选自:H、C1~C8烷基,羟基取代的C1~C8烷基,C1~C8烷氧基取代的C1~C8烷基、C3~C8环烷基、3~18元杂环烷基、C1~C8酰基、烯基酰基、磺酰基、5~18元杂芳基;或者R7、R8与和其相连的N原子一起形成取代或者未取代的3-10元杂环基,或者R7、R8与和其相连的N原子一起形成取代或者未取代的5~10元杂芳基;
n选自:0-6之间的整数;
各R9分别独立地任选自:H、卤素、C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、C1~C18烷胺基、氨基、羟基、氰基、硝基、酯基、乙酰基、丙酰基、丁酰基、酰胺基、磺酰基、磺酰氨基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基、5~18元杂芳基;当R9选自C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、C1~C18烷胺基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基或5~18元杂芳基,所述R9独立任选地被1个或多个R4取代。
7.根据权利要求3所述的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子,其特征在于,各R7,R8分别独立地任选自:H、C1~C8烷基,羟基取代的C1~C8烷基,C1~C8烷氧基取代的C1~C8烷基、C3~C8环烷基、3~18元杂环烷基、C1~C8酰基、烯基酰基、磺酰基、5~18元杂芳基;或者R7、R8与和其相连的N原子一起形成如下结构:
m,n分别独立地选自:0-6之间的整数;
各R9分别独立地任选自:H、卤素、C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、C1~C18烷胺基、氨基、羟基、氰基、硝基、酯基、乙酰基、丙酰基、丁酰基、酰胺基、磺酰基、磺酰氨基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基、5~18元杂芳基;当R9选自C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、C1~C18烷胺基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基或5~18元杂芳基时,所述R9独立任选地被1个或多个R4取代;
各R10分别独立地任选自:H、卤素、C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、C1~C18烷胺基、氨基、羟基、氰基、硝基、酯基、乙酰基、丙酰基、丁酰基、酰胺基、磺酰基、磺酰氨基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基、5~18元杂芳基;当R10选自C1~C18烷基、C3~C18环烷基、3~18元杂环烷基、C1~C18烷氧基、C1~C18烷胺基、C6~C18芳基、C6~C18芳基取代的C1~C18烷基或5~18元杂芳基时,所述R10独立任选地被1个或多个R11取代;
各R11分别独立地任选自:H、羟基、氨基、氰基、硝基、卤素、C1~C6烷氧基、C1~C6烷基、磷酸基、二甲基胺基。
9.根据权利要求7所述的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子,其特征在于,
各R9分别独立地任选自:H、卤素、C1~C6烷基、C3~C8环烷基、3~8元杂环烷基、C1~C6烷氧基、C1~C6烷胺基、氨基、羟基、氰基、硝基、酯基、酰胺基、磺酰基、磺酰氨基、C6~C10芳基、C6~C10芳基取代的C1~C10烷基、5~10元杂芳基;当R9选自C1~C6烷基、C3~C8环烷基、3~8元杂环烷基、C1~C6烷氧基、C1~C6烷胺基、C6~C10芳基、C6~C10芳基取代的C1~C6烷基或5~10元杂芳基时,所述R9独立任选地被1个或多个R4取代;
各R10分别独立地任选自:H、C1~C6烷基、C3~C8环烷基、3~8元杂环烷基、C1~C6烷氧基、C1~C6烷胺基、氨基、羟基、氰基、硝基、酯基、乙酰基、丙酰基、丁酰基、酰胺基、磺酰基、磺酰氨基、C6~C10芳基、C6~C10芳基取代的C1~C10烷基、5~10元杂芳基;当R10选自C1~C6烷基、C3~C8环烷基、3~8元杂环烷基、C1~C6烷氧基、C1~C6烷胺基、C6~C10芳基、C6~C10芳基取代的C1~C6烷基或5~10元杂芳基时,所述R10独立任选地被1个或多个R11取代。
10.根据权利要求9所述的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子,其特征在于,
各R9分别独立地任选自:H、C1~C3烷基;
各R10分别独立地任选自:H、C1~C3烷基、R11取代的C1~C3烷基;R11选自:羟基、二甲基氨基。
12.根据权利要求3所述的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子,其特征在于,各R5分别独立地任选自:H、卤素、C1~C6烷基、C3~C8环烷基、3~8元杂环烷基、C1~C6烷氧基、C1~C6烷胺基、氨基、羟基、氰基、硝基、酯基、酰胺基、磺酰基、磺酰氨基、C6~C10芳基、C6~C10芳基取代的C1~C6烷基、5~10元杂芳基;当R5选自C1~C6烷基、C3~C8环烷基、3~8元杂环烷基、C1~C6烷氧基、C1~C6烷胺基、C6~C10芳基、C6~C10芳基取代的C1~C6烷基或5~10元杂芳基时,所述R5独立任选地被1个或多个R4取代。
13.根据权利要求12所述的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子,其特征在于,各R5分别独立地任选自:H、C1~C6烷基、C1~C6烷氧基、羟基。
14.根据权利要求13所述的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子,其特征在于,各R5分别独立地任选自:甲氧基、乙氧基。
15.根据权利要求3所述的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子,其特征在于,各R6分别独立地任选自:H、卤素、C1~C6烷基、C3~C8环烷基、3~8元杂环烷基、C1~C6烷氧基、C1~C6烷胺基、氨基、羟基、氰基、硝基、酯基、酰胺基、磺酰基、磺酰氨基、C6~C10芳基、C6~C10芳基取代的C1~C6烷基、5~10元杂芳基;当R6选自C1~C6烷基、C3~C8环烷基、3~8元杂环烷基、C1~C6烷氧基、C1~C6烷胺基、C6~C10芳基、C6~C10芳基取代的C1~C6烷基或5~10元杂芳基时,所述R6独立任选地被1个或多个R4取代。
16.根据权利要求15所述的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子,其特征在于,各R6分别独立地任选自:H、卤素、C1~C6烷基、C1~C6烷氧基、三氟甲基;并且X6、X7、X8、X9和X10中至少有一个选自CR6,至少有一个R6不为氢。
17.根据权利要求16所述的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子,其特征在于,各R6分别独立地任选自:H、F、Cl、甲基、三氟甲基、甲氧基;并且X6、X7、X8、X9和X10中至少有一个选自CR6,至少有一个R6不为氢。
18.根据权利要求1-17任一项所述的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子,其特征在于,A1和B1为N;A2、B2、D和E为CR2;X为O。
19.根据权利要求1-17任一项所述的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子,其特征在于,R1任选自:H、C1~C6烷基、羟基取代的C1~C6烷基、对甲氧基苄基。
20.根据权利要求19所述的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子,其特征在于,R1任选自:H、甲基、乙基、丙基、异丙基,羟乙基、对甲氧基苄基。
22.权利要求1-21任一项所述的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子在制备RIOK2抑制剂中的应用。
23.权利要求1-21任一项所述的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子在制备预防或者治疗肿瘤的药物中的应用。
24.根据权利要求23所述的应用,其特征在于,所述肿瘤为:非小细胞肺癌、小细胞肺癌、肺腺癌、肺鳞癌、胰腺癌、乳腺癌、前列腺癌、肝癌、皮肤癌、上皮细胞癌、胃肠间质瘤、白血病、组织细胞性淋巴癌、鼻咽癌、胶质瘤、骨肉瘤、胃癌、皮肤鳞癌、卵巢癌。
25.一种预防或者治疗肿瘤的药用组合物,其特征在于,由活性成分和药学上可接受的辅料制备得到,所述活性成分包括权利要求1-21任一项所述的含氮并杂环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911194164 | 2019-11-28 | ||
CN2019111941641 | 2019-11-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112851667A true CN112851667A (zh) | 2021-05-28 |
CN112851667B CN112851667B (zh) | 2022-09-09 |
Family
ID=75996334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011294834.XA Active CN112851667B (zh) | 2019-11-28 | 2020-11-18 | 含氮并杂环类化合物及其药用组合物和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112851667B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023155826A1 (zh) * | 2022-02-17 | 2023-08-24 | 暨南大学 | 一类多取代三环并杂环化合物及其药用组合物和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107205993A (zh) * | 2014-12-06 | 2017-09-26 | 细胞内治疗公司 | 有机化合物 |
CN109071535A (zh) * | 2016-04-19 | 2018-12-21 | 先天肿瘤免疫公司 | Nlrp3调节剂 |
-
2020
- 2020-11-18 CN CN202011294834.XA patent/CN112851667B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107205993A (zh) * | 2014-12-06 | 2017-09-26 | 细胞内治疗公司 | 有机化合物 |
CN109071535A (zh) * | 2016-04-19 | 2018-12-21 | 先天肿瘤免疫公司 | Nlrp3调节剂 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023155826A1 (zh) * | 2022-02-17 | 2023-08-24 | 暨南大学 | 一类多取代三环并杂环化合物及其药用组合物和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112851667B (zh) | 2022-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5756518B2 (ja) | 複素環アルキニルベンゼン化合物と、その医療用組成物および使用 | |
CN105601573B (zh) | 2-氨基嘧啶类化合物及其药物组合物和应用 | |
CN106467541B (zh) | 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用 | |
CN104418860B (zh) | 嘧啶并杂环类化合物及其药用组合物和应用 | |
CN102816162B (zh) | 嘧啶并嘧啶酮类化合物及其药用组合物和应用 | |
CN103012399B (zh) | 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用 | |
EP2976334A1 (en) | Diaminoheteroaryl substituted indazoles | |
WO2019015593A1 (zh) | 嘧啶并吡啶酮或者吡啶并吡啶酮类化合物及其应用 | |
CN112851667B (zh) | 含氮并杂环类化合物及其药用组合物和应用 | |
CN103374000B (zh) | 嘧啶并二氮杂卓类化合物及其药用组合物和应用 | |
CN112351971B (zh) | 喹啉或喹唑啉类化合物及其应用 | |
CN115515589A (zh) | Ulk1/2抑制剂及其使用方法 | |
CN114539263B (zh) | 一类含氮并杂环化合物及其药用组合物和应用 | |
CN113966331B (zh) | 含脲结构的三芳环化合物及其应用 | |
CN112313213B (zh) | 3-氨基吡唑类化合物及其应用 | |
CN103570731B (zh) | 嘧啶并三环或嘧啶并四环类化合物及其药用组合物和应用 | |
WO2022148317A1 (zh) | 2-氨基嘧啶类化合物及其药物组合物和应用 | |
US20230348462A1 (en) | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors | |
WO2023246903A1 (zh) | 含硒杂环类化合物及其药用组合物和应用 | |
CN116063283A (zh) | 3-氨基吲唑类化合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231024 Address after: Building 4, No. 6158 Nanting Road, Tinglin Town, Jinshan District, Shanghai, 201500 Patentee after: SHANGHAI LANMU CHEMICALS Co.,Ltd. Address before: 510700 No. 601, Huangpu Avenue West, Tianhe District, Guangzhou City, Guangdong Province Patentee before: Jinan University |
|
TR01 | Transfer of patent right |